The QualityStocks Daily Friday, December 4th, 2020

Today's Top 3 Investment Newsletters

Tip.us(LTTGF) +150.00%

QualityStocks(USMJ) +100.00%

SmallCapVoice(MCOA) +92.98%

The QualityStocks Daily Stock List

ContraFect Corporation (CFRX)

BioPharmCatalyst, Morningstar, TradingView, Zacks, Stock Analysis, YCharts, Proactive Investors, Stockwatch, Optionslam.com, ETF.com, Market Screener, StockNews, The Baxter Report, Invest Chronicle, The Stock Market Watch, Stocktwits, Street Insider, Investing.com, Wallet Investor, Stockhouse, GuruFocus, InvestorsHub, Invest Million, Simply Wall St, Nasdaq, ETF Channel, Seeking Alpha, TMXmoney, Investors Observer, MacroTrends, GlobeNewswire, News RTS, NasdaqTrader, GlobeNewswire, and Stock Monitor reported earlier on ContraFect Corporation (CFRX), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

A clinical-stage biotechnology enetrprise, ContraFect Corporation focuses on discovering and developing direct lytic agents (DLAs), including lysins and amurin peptides, for the treatment of life-threatening infectious diseases. Its belief is that the properties of its lysins and amurin peptides will make them suitable for targeting antibiotic-resistant organisms, including methicillin-resistant Staph aureus (MRSA) and P. aeruginosa that can cause serious infections such as bacteremia, pneumonia, and osteomyelitis. Established in 2008, ContraFect is based in Yonkers, New York. The Company’s shares trade on the Nasdaq Global Select Market (NasdaqGS).

Lysins are a new class of DLAs. They are recombinantly produced antimicrobial proteins with a novel mechanism of action associated with the fast killing of target bacteria, eradication of biofilms, and synergy with conventional antibiotics. Amurin peptides are a novel class of DLAs. They exhibit broad-spectrum activity against a wide array of antibiotic-resistant Gram-negative pathogens.

The Company has completed a Phase 2 clinical trial for the treatment of Staph aureus bacteremia, including endocarditis, with its lead lysin candidate, exebacase, which is the first lysin to enter clinical studies in the U.S. Exebacase (CF-301) is a lysin with potent activity against Staphylococcus aureus (Staph aureus).

Exebacase has the potential to be the first-in-class of a new treatment for patients with Staph aureus bacteremia. Exebacase, now undergoing study in a pivotal Phase 3 clinical study, was granted Breakthrough Therapy designation by the Food and Drug Administration (FDA) for the treatment of MRSA bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients.

The focus of ContraFect’s research and discovery efforts is on identifying and engineering lysins that selectively kill specific species of Gram-negative bacteria. Additionally, concerning amurins, the Company has discovered a new class of phage-encoded lytic antimicrobial peptides, which have potent in vitro activity across a wide assortment of resistant Gram-negative pathogens. These include species that are part of the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species).

Recently, ContraFect announced that it initiated an expanded access program to provide exebacase for the treatment of persistent bacteremia caused by methicillin-resistant Staphylococcus aureus (MRSA) in COVID-19 patients. ContraFect is providing expanded access to exebacase under a treatment protocol available to clinical sites participating in the continuing Phase 3 study, which enables physicians to use exebacase to treat severely ill COVID-19 patients with persistent MRSA bacteremia, despite treatment with standard of care antibiotics. These patients who are hospitalized with COVID-19 may now have access to exebacase since they are not eligible to participate in the ongoing Phase 3 study.

In November, ContraFect announced financial results and business updates for Q3 ended September 30, 2020. Mr. Roger J. Pomerantz, M.D., President, Chief Executive Officer, and Chairman of ContraFect, said, “We are pleased with the progress of the Phase 3 DISRUPT superiority study of exebacase, which received Breakthrough Therapy designation from the FDA earlier this year, in patients suffering from life-threatening Staph aureus bloodstream infections. We also continue to advance our pipeline programs towards the clinic and appreciate the tremendous financial support from CARB-X and the Cystic Fibrosis Foundation for our second product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa.”

ContraFect Corporation (CFRX), closed Saturday's trading session at $5.66, up 0.53286%, on 130,720 volume with 851 trades. The average volume for the last 3 months is 186,215 and the stock's 52-week low/high is $2.90000009/$13.3990001.

Heat Biologics, Inc. (HTBX)

BioPharmCatalyst, Zacks, StockNews, Whale Wisdom, Business Insider, Stock Analysis, Nasdaq, BioPharmaJournal, News Daemon, YCharts, The Stock Market Watch, Stockhouse, Netcials, Stocktwits, DBT News, Finviz, Market Chameleon, Newsheater, ChartMill, InvestMillion, ETF.com, Invest Chronicle, TMXmoney, Investing.com, Proactive Investors, Morningstar, Barchart, InvestorsHub, Simply Wall St, MacroTrends, DBT News, Market Screener, Investors Observer, Seeking Alpha, TradingView, and Currency.com reported earlier on Heat Biologics, Inc. (HTBX), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Heat Biologics, Inc. is a clinical-stage biopharmaceutical company. It focuses on developing first-in-class therapies to modulate the immune system. This includes many oncology product candidates as well as a novel COVID-19 vaccine product candidate. The Company has a proprietary gp96 platform to activate immune responses against pathogenic or cancer antigens.

Heat Biologics has its head office in Morrisville, North Carolina. The Company also has operations in San Antonio, Texas. Heat Biologics lists on the Nasdaq Capital Market (NasdaqCM).

Heat Biologics has numerous product candidates in development taking advantage of the the gp96 platform. These include HS-110, which has completed enrollment in its Phase 2 trial; HS-130 in Phase 1; and a COVID-19 vaccine program in preclinical development.

Furthermore, the Company is developing a pipeline of proprietary immunomodulatory antibodies. This includes PTX-35, which is enrolling in a Phase 1 trial.

This past October, Heat Biologics announced it was issued a new US patent (US Patent No. 10,780,161) covering compositions of matter, which are part of the Company's gp96 platform (antigen presentation, T cell activation, TLR activation) in combination with Inducible T cell Co-stimulator (ICOS) ligand or ICOSL, a T cell immune booster, in a single therapy. The objective of the combination therapy is to increase immunity to potentially overcome the immunosuppressive tumor microenvironment and address the needs of patients refractory to present therapies. Heat Biologics’ gp96 combination with a T cell co-stimulator is expected to have utility in combating viral infections, beyond its potential in oncology.

Recently, Heat Biologics provided financial, clinical, and operational updates for Q3 ended September 30, 2020. The Company recognized $0.8 million of Grant Revenue for qualified expenditures under the CPRIT and NIH Grant. No Grant Revenue was recognized under the respective Grants for the three months ended September 30, 2019. The increase in Grant Revenue in the current-year period mainly reflects the expected timing of completion of deliveries under the present phase of the contracts.

Net Loss Attributable to Heat Biologics was roughly $8.9 million, or ($0.06) per basic and diluted share for the quarter ended September 30, 2020. This is in comparison to a Net Loss of roughly $6.2 million, or ($0.18) per basic and diluted share for the quarter ended September 30, 2019.

Heat Biologics, Inc. (HTBX), closed Saturday's trading session at $1.06, off by 3.6364%, on 3,611,831 volume with 5,405 trades. The average volume for the last 3 months is 7,163,501 and the stock's 52-week low/high is $0.194999992/$4.30000019.

International Battery Metals Ltd. (RHHNF)

Stock of the Week, Central Charts, WallStreetAlerts, MarketWatch, Junior Mining Network, Market Screener, Fintel, Morningstar, Nasdaq, GuruFocus, TipRanks, Wallet Investor, Insider Financial, TradingView, The Globe and Mail, Dividend Investor, Dividend.com, PR Newswire, Newsfilecorp, Seeking Alpha, Barron’s, Market Wire News, ADVFN.com, Wallmine, TheCSE.com, Simply Wall St, MarketBeat, Barchart, OTC Markets, docoh, OilandGas360, Green Leaf Pot Stocks, Valuu.io, and Stockhouse reported earlier on International Battery Metals Ltd. (RHHNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets, International Battery Metals Ltd. is an advanced disruptive technology enterprise. The Company’s emphasis is on lithium brine extraction. It is in the process of creating and applying intellectual property (IP) related to lithium extraction from brines. The Company previously went by the name Rheingold Exploration Corp. It changed its name to International Battery Metals Ltd. in August of 2017. Established in 2010, International Battery Metals is based in Vancouver, British Columbia.

Lithium extraction from brine is the next disruptive technology. Third generation patent pending technology allows lithium extraction from South American salars and drill holes associated with the oil and gas industry globally. International Battery Metals’ competitive advantage is that it produces high quality battery grade lithium for lithium-ion batteries.

Extraction specifically targets lithium chloride; other salts stay in the brine. Moreover, there is a small environmental footprint: no salt piles, waste, water ponds or rock piles. It is efficient simple processing, a low carbon footprint, and allows for very low fresh water usage.

International Battery Metals has a technical team with wide-ranging proven experience in lithium extraction projects. The Company is targeting low-cost production of battery grade lithium and has innovative mobile extraction units for efficient timely deployment. Its focus is to bring on resources quickly with high recovery rates.

Phase 2 engineering is completed on the mobile extraction system. The design of International Battery Metals’ process is to recycle roughly 95 percent of its process water. The Company has License Agreements with Sorcia Minerals LLC for Chile and Argentina. It receives a 6 percent royalty for all products sold under agreements. The Company has a 10 percent interest in Sorcia Minerals. Sorcia is a subsidiary of Ensorcia Metal Corporation.

This past October, International Battery Metals announced that it completed a private placement with Sorcia Minerals of 25,000,000 common shares at a price of $0.10 for proceeds of $2,500,000 as announced September 3, 2020. The proceeds are being used to continue fabrication of International Battery Metals’ first lithium extraction unit that is well underway, as well as for general corporate purposes.

International Battery Metals Ltd. (RHHNF), closed Saturday's trading session at $0.17075, off by 27.1855%, on 151,030 volume with 36 trades. The average volume for the last 3 months is 69,914 and the stock's 52-week low/high is $0.0511/$0.169699996.

Macarthur Minerals Limited (MMSDF)

Proactive Investors, Resource World, Northern Miner, The Online Investor, Nasdaq, InvestorsHub, Junior Mining Network, The Prospector News, Wallet Investor, Street Insider, Mining Capital, Stockwatch, MarketWatch, GuruFocus, Mining Stock Education, Morningstar, Market Screener, Investing.com, PR Newswire, Simply Wall St, Annual Reports, GlobeNewswire, Investing News, Barchart, Stockhouse, TMXmoney, Global Banking and Finance, TradingView, OTC Markets, 24hgold, Fintel, Mining News Feed, and Seeking Alpha reported previously on Macarthur Minerals Limited (MMSDF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Macarthur Minerals Limited is an iron ore development, gold, and lithium exploration company. It concentrates on bringing to production its 100 percent owned Western Australia iron ore projects. The OTCQB-listed Company formerly went by the name Macarthur Diamonds Limited. It changed its name to Macarthur Minerals Limited in July of 2005. The Company has its head office in Toowong, Australia.

The Lake Giles Iron Project mineral resources include the Ularring hematite resource (approved for development) comprising Indicated resources of 54.5 million tonnes at 47.2 percent Fe and Inferred resources of 26 million tonnes at 45.4 percent Fe; and the Lake Giles magnetite resource of 53.9 million tonnes (Measured), 218.7 million tonnes (Indicated) and 997 million tonnes (Inferred).

The Lake Giles Iron Project continues to advance, with the filing of a NI 43-101 technical report for the project’s magnetite Mineral Resource in October 2020, alongside the completion of conceptual engineering design work for a proposed ‘Helix’ dumper rail unloading solution at the Esperance Port.

Macarthur Minerals has prominent (a roughly 721 square kilometer tenement area) gold, lithium, and copper exploration interests in the Pilbara region of Western Australia. In addition, the Company has lithium brine claims in the emerging Railroad Valley region in Nevada. Macarthur Minerals has retained 100 percent ownership of its Pilbara tenements, following the ending of an earn in agreement for non-iron assets with FE Limited.

The Company has secured a binding Life-of-Mine Off-Take Agreement with Glencore International A.G. and is centered on commercializing its iron ore projects utilizing mining, processing, and logistics infrastructure in the region. It is progressing towards completing a bankable Feasibility Study (FS).

Regarding its Gold Strategy, Macarthur Minerals states that it has created a very valuable portfolio of conglomerate/greenstone gold tenements in the Pilbara Region of Western Australia. This portfolio consists of 11 granted Exploration Licenses. The Company’s 100 percent owned Hillside Gold Project will be the priority exploration focus as these tenements have had existing historic small-scale gold mining activity. Greater than 700 oz of gold nuggets have been found by prospectors on these tenements. The Exploration Licenses were progressively granted during November/December 2017.

Pertaining to Nevada Lithium, Macarthur Minerals, through its wholly-owned U.S. subsidiary, Macarthur Lithium Nevada Limited, staked 210 new unpatented placer mining claims at its new Reynolds Springs Lithium Brine Project (Reynolds Springs Project) in the Railroad Valley, Nevada. The claims are situated near the town of Currant, in Nye County, Nevada. The Reynolds Springs Project is positioned about 180 miles (300 km) North of Las Vegas, Nevada, and 330 miles (531 km) South East of Tesla’s Gigafactory.

This week, Macarthur Minerals announced the appointment of Mr. Andrew Bruton as its new Chief Executive Officer (CEO). Ms. Mima Wirakara has been appointed to take over the role of Company Secretary. Macarthur Minerals’ present CEO, Mr. Joe Phillips, will assume the role of Managing Director, concentrating on North American and Australian capital markets, project funding, and also takeover awareness. Furthermore, Executive Chairman Cameron McCall’s designation has changed to Non-Executive Chairman.

Macarthur Minerals Limited (MMSDF), closed Saturday's trading session at $0.354, off by 1.8194%, on 29,424 volume with 7 trades. The average volume for the last 3 months is 34,544 and the stock's 52-week low/high is $0.04385/$0.502600014.

Mill City Ventures III, Ltd. (MCVT)

Speculating Stocks, StockTrot, Street Insider, CRWE World, Whale Wisdom, Business Insider, OTC Markets, Morningstar, Webull, Macroaxis, Dividend Investor, MarketBeat, DNB.com, Market Screener, Stockopedia, TipRanks, Invezz.com, GuruFocus, Stockhouse, PR Newswire, Barron’s, Nasdaq, Seeking Alpha, Fintel, The Globe and Mail, last10k, Stockwatch, Bloomberg, MarketWatch, YCharts, Barchart, docoh, and FX Empire reported earlier on Mill City Ventures III, Ltd. (MCVT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Mill City Ventures III, Ltd. is a short-term non-bank lending and specialty finance company. It helps companies and individual borrowers via loan and specialty finance options. The Company previously went by the name Poker Magic, Inc. Established in January 2006, Mill City Ventures III has its corporate headquarters in Wayzata, Minnesota. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Mill City Ventures III typically loans to private companies. It brings the cash necessary for borrowers to fund their operations. This whether it’s real estate bridge mortgages and loans, cash for operations, or general purpose loans with sufficient collateral.

In essence, the Company operates as a business development enterprise specializing in investments in debt and equity securities of public and private companies to fund their operations whether its start-up, acquisition, or growth. Mill City Ventures III mainly concentrates on investing in, lending to, and making managerial assistance available to privately held and publicly traded companies. In addition, it advises its portfolio companies with respect to finance and operations.

Last month, Mill City Ventures III announced that its Net Income for the three months ended September 30, 2020 was $106,088, or $0.01 per share. This is in comparison to a Loss of $146,699 for the same period a year ago. Total Revenue for the quarter was $287,034. This is in comparison to $43,007 for the same period a year ago.

Net Income for the nine-month period ending Sept. 30, 2020 was $255,221. This is in comparison to a Loss of $543,618 for the same period a year ago. Total Revenue for the nine-month period was $755,469. This is in comparison to $125,375 for the same period a year ago. Moreover, during the nine-month period, Net Asset Value increased from $10.14M at December 31, 2019 to $10.86M at September 20, 2020.

Mill City Ventures III, Ltd. (MCVT), closed Saturday's trading session at $1.05, even for the day, on 4,600 volume. The average volume for the last 3 months is 1,022 and the stock's 52-week low/high is $0.430000007/$1.04999995.

RealNetworks, Inc. (RNWK)

Zacks, Stocktwits, Equities.com, Invest Million, Investors Observer, Stockhouse, PR Newswire, Wallet Investor, Market Screener, Morningstar, Finviz, MarketWatch, Invest Chronicle, Stocknews, DBT News, MZP News, AI Stock Finder, ETF.com, Nasdaq, Seeking Alpha, Wallmine, Morningstar, Simply Wall Street, last10k, GuruFocus, TMXmoney, Dividend Investor, YCharts, ChartMill, MarketBeat, MacroTrends, and EarningsCast reported beforehand on RealNetworks, Inc. (RNWK), and we today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

RealNetworks, Inc. has a legacy of digital media expertise and innovation. The Company has created a new generation of products that use best-in-class artificial intelligence (AI) and machine learning to enhance and secure daily lives. The Company provides network-delivered digital media applications and services to manage, play, as well as share digital media. RealNetworks is based in Seattle, Washington. The Company lists on the NasdaqGS (Nasdaq Global Select Market).

RealNetworks’ products include SAFR and Kontxt. SAFR is the world’s premier facial recognition platform for live video. SAFR leads in real world performance and accuracy as evidenced in testing by NIST. SAFR enables new applications for security, convenience, and analytics. SAFR can be deployed on premises, in the cloud, or with a VMS.

SAFR from RealNetworks now has its SAFR® Inside. This is a new app component of its Facial Recognition and Computer Vision Platform, which runs on ACAP enabled cameras with edge processing capabilities. SAFR Inside lessens network traffic and server overhead and therefore reduces overall deployment costs.

Kontxt is the leading platform for categorizing A2P messages to help mobile carriers build customer loyalty and increase new revenue via text message classification and antispam. One can take a stream of messages and let Kontxt™ analyze and classify them. Therefore, one can deliver the right messages to the right recipients, at the right price, and with the right service characteristics. Moreover, a user gets next-generation spam and gray route detection. The Company’s other product offerings include RealMedia® HD, Mobile Carrier Services, GameHouse, RealPlayer, and RealTimes.

This week, Setelsa Security, an Amper Group company and 30 year industry expert in secure access and time and attendance control systems, announced it selected SAFR from RealNetworks to provide face-based biometrics for its clients in the United Kingdom (UK), Spain, Portugal, Mexico, and Argentina. Integrating SAFR face recognition will enhance Setelsa’s secure access solutions. This will enable clients to deploy touchless, face-based authentication. This partnership integrates SAFR’s AI-based computer vision technology — face detection, face recognition, and mask detection — into Setelsa’s market-leading secure access solutions.

RealNetworks, Inc. (RNWK), closed Saturday's trading session at $1.55, off by 1.8987%, on 119,845 volume with 776 trades. The average volume for the last 3 months is 404,344 and the stock's 52-week low/high is $0.319999992/$2.24.

Strongbridge Biopharma plc (SBBP)

Zacks, MacroTrends, GuruFocus, Market Chameleon, Stocktwits, Whale Wisdom, GlobeNewswire, StockNews, MarketBeat, Stockhouse, Fintel, ETF.com, The Globe and Mail, Barchart, Market Screener, DBT News, MarketWatch, Bloomberg, Invest Chronicle, PR Newswire, Seeking Alpha, Investors Observer, Finviz, Simply Wall St, Barron’s, Morningstar, Investing.com, YCharts, Business Insider, and Nasdaq reported earlier on Strongbridge Biopharma plc (SBBP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Strongbridge Biopharma plc is an international commercial-stage biopharmaceutical company. Its focus is on the development and commercialization of therapies for rare diseases with significant unmet needs. The Company’s rare endocrine franchise includes RECORLEV® (levoketoconazole) and veldoreotide extended release. The Company previously went by the name Cortendo plc. It changed its name to Strongbridge Biopharma plc in September of 2015. Established in 1996 and NasdaqGS-listed, Strongbridge Biopharma has its corporate headquarters in Trevose, Pennsylvania.

RECORLEV® (levoketoconazole) is a cortisol synthesis inhibitor presently being studied in Phase 3 clinical studies for the treatment of endogenous Cushing’s syndrome. Veldoreotide extended release is a pre-clinical next-generation somatostatin analog being investigated for the treatment of acromegaly and potential additional applications in other conditions amenable to somatostatin receptor activation.

RECORLEV and veldoreotide have received orphan drug designation from the FDA (Food and Drug Administration) and the European Medicines Agency. Strongbridge’s rare neuromuscular franchise includes KEVEYIS® (dichlorphenamide). This is the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis. KEVEYIS has orphan drug exclusivity in the USA.

In November, Strongbridge Biopharma announced that secondary endpoint results from the Phase 3 SONICS study of RECORLEV™ (levoketoconazole) for the potential treatment of endogenous Cushing’s syndrome were published online in advance of print publication in the peer-reviewed journal, Pituitary, the official publication of the Pituitary Society and the Growth Hormone Research Society. Endogenous Cushing’s syndrome is a rare, serious and potentially lethal endocrine disease caused by chronic elevated cortisol exposure - often the result of a benign tumor of the pituitary gland.

The manuscript, entitled “Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome,” includes analyses demonstrating that treatment with RECORLEV led to noteworthy improvements in Cushing’s syndrome signs and symptoms, patient-reported quality of life (QoL) outcomes, depression symptoms, as well as testosterone levels.

Strongbridge Biopharma is on track to submit a New Drug Application (NDA) for RECORLEV® (levoketoconazole) to the FDA in Q1 of 2021 following the reporting of positive top-line data from the LOGICS Study in Q3 of 2020. In addition, the Company reported KEVEYIS® (dichlorphenamide) Q3 2020 Revenue of $8.1 Million. This represents a 42 percent increase in Revenue versus $5.7 Million during Q3 of 2019.

Strongbridge Biopharma plc (SBBP), closed Saturday's trading session at $2.84, up 1.4286%, on 311,791 volume with 1,979 trades. The average volume for the last 3 months is 620,065 and the stock's 52-week low/high is $1.50/$4.63000011.

North American Cannabis Holdings, Inc. (USMJ)

Pink Investing, Wolf Street, GlobeNewswire, PotStockNews, Emerging Growth, SmallCap Exclusive, Investor Ideas, Morningstar, Market Exclusive, Micro Small Cap, hot Stocked, Marijuana Stocks Report, PR Newswire, Simply Wall St, Dividend Investor, Real Investment Advice, Accesswire, Infront Analytics, Tech Stock Observer, Pitchbook, MJ Invest, GuruFocus, Research Pool, Nasdaq, Daily Marijuana Observer, P&T Community, Stockhouse, Investors.com, Insider Financial, Seeking Alpha, BioSpace, Wallet Investor, and InvestorsHub reported beforehand on North American Cannabis Holdings, Inc. (USMJ), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

North American Cannabis Holdings, Inc., via its subsidiaries, operates in the legal cannabis market in the US. It conducts various pilots in the legal cannabis sector so as to explore different high growth potential business opportunities. The Company previously went by the name Algae International Group, Inc. It changed its name to North American Cannabis Holdings, Inc. in June of 2015. North American Cannabis Holdings is headquartered in Farmers Branch, Texas and lists on the OTC Markets.

Additionally, North American Cannabis operates a destination beverage company. It enables consumers to interface with staff to learn about the specific benefits of cannabis, and select healthy and refreshing cannabis infused beverages. These beverages include custom blended hemp infused coffee, cold pressed juices, and smoothies. Furthermore, the Company offers raw hemp seeds and other hemp infused foods.

North American Cannabis’ eCommerce site is www.USMJ.com. USMJ is a subsidiary company of North American Cannabis Holdings. USMJ partners with premier CBD producers. USMJ curates each product selection to work as promised and to ensure each item it sells is safe and effective.

North American Cannabis has a curated product line of legal cannabinoids and accessories. All of the Company’s products are lab-tested and contain no THC (tetrahydrocannabinol) through a carefully monitored extraction process. North American Cannabis’ products are all natural, all safe, and all CBD (cannabidiol). The Company carries manifold CBD and CBG Smokable products in Pre Roll and Flower. It has greater than 150 CBD, Hemp, as well as Cannabis Essentials products available online.

This past June, North American Cannabis Holdings said that because of overwhelming demand, USMJ.com has streamlined its process to becoming a Vendor on USMJ.com. The USMJ.com Vendor program launched earlier but has been a slowly growing process.

Now, CBD/CBG Manufacturers and Vendors can apply and list their products on USMJ.com. Before now, it's been a series of emails. However, now there's a set discovery process to understand the products the Company is putting online and established marketing efforts to help businesses grow.

North American Cannabis Holdings, Inc. (USMJ), closed Saturday's trading session at $0.0003, up 100.00%, on 785,543,194 volume with 359 trades. The average volume for the last 3 months is 22,092,291 and the stock's 52-week low/high is $0.000099999/$0.0003.

Blue Dolphin Energy Co. (BDCO)

Investor Village, Zacks, Stocktwits, CSI Market, Central Charts, Morningstar, Seeking Alpha, Annual Reports, Stockopedia, Accesswire, Finbox, hot Stocked, Investing.com, 4-Traders, Simply Wall St, Annual Reports, Stockhouse, Market Exclusive, TipRanks, last10k, GuruFocus, Barchart, Proactive Investors, InvestorsHub, and StockInvest.us reported beforehand on Blue Dolphin Energy Co. (BDCO), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Blue Dolphin Energy Co. is primarily an independent refiner and marketer of petroleum products. The Company’s main asset is a 15,000 barrel per day (bpd) crude oil and condensate processing facility located in Nixon, Wilson County, Texas (Nixon Facility). In addition, as part of its refinery business segment, Blue Dolphin Energy also conducts petroleum storage and terminaling operations under third-party lease agreements at the Nixon Facility. The Company also owns and operates pipeline assets and has leasehold interests in oil and gas properties. OTCQX-listed and founded in 1986,, Blue Dolphin Energy is based in Houston, Texas.

Blue Dolphin Energy’s assets include Lazarus Energy, LLC (Refining Assets); and Blue Dolphin Pipe Line Company (Pipeline Assets). Its additional wholly-owned subsidiaries are Lazarus Refining & Marketing, LLC; Blue Dolphin Petroleum Company (Oil and Gas Leasehold Interests); Blue Dolphin Exploration Company (Exploration and Production); Blue Dolphin Services Co. (Administrative Services); and Petroport, Inc.

Blue Dolphin Pipe Line Company owns interests in and operates the Blue Dolphin Pipeline System (BDPS), which includes about 38 miles of pipeline from the Blue Dolphin Pipeline, onshore facilities and acreage in Freeport, Texas. Moreover, Blue Dolphin Pipe Line Company owns the Galveston Area Block 350 Pipeline and the Omega Pipeline.

The Nixon Crude Oil Processing Facility (Nixon Facility-56-acre) is near the border of Gonzales and Wilson Counties in Nixon, Texas, which lies in the heart of the Eagle Ford Shale and is within close proximity to some of the highest producing wells drilled in the Eagle Ford Shale so far. The Nixon Facility separates input crude oil and condensate into distillates (i.e. jet fuel) for sale into nearby markets, and also naphtha and atmospheric gas oil for sale to nearby refineries for further processing. Along with the processing capacity, the Nixon Facility has a storage capacity of 295,000 barrels.

Blue Dolphin Energy Co. (BDCO), closed Saturday's trading session at $0.23, up 84.00%, on 63,645 volume with 32 trades. The average volume for the last 3 months is 8,577 and the stock's 52-week low/high is $0.05/$0.939999997.

Edgewater Wireless Systems, Inc. (KPIFF)

OTC Markets, Stockhouse, StockPulse, TalkMarkets, Capital Cube, Stockwatch, Insider Tracking, Trading View, GuruFocus, Wallet Investor and MarketWatch reported earlier on Edgewater Wireless Systems, Inc. (KPIFF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Edgewater Wireless Systems, Inc. focuses on Wi-Fi infrastructure with its patented WiFi3™ technology and Next Generation Access Points. The Company commercializes innovative wireless technologies for the service provider market. It is developing considerably improved Wi-Fi network performance across an array of industries and challenging environments with top-notch performance, high flexibility, and consummate security. Established in 1988 by Edgewater Computer Systems, Edgewater Wireless Systems is based in Ottawa, Ontario. The Company lists on the OTC Markets Group’s OTCQB.

Edgewater Wireless Systems has two distinct directions. One is in the Enterprise market, where the Company has validated its unique technology design with players such as Kroger and Mediacom. The second is the massive Consumer (Home) market where Edgewater has made major progress with its alliance with CableLabs.

Edgewater Wireless has a global distribution network and the Company has invested greater than $50 Million in the development of Edgewater Wireless Products. It has sales partners in the United States, the United Kingdom (UK), Brazil, Peru, and Asia.

Edgewater Wireless is patented, standards-compliant Wi-Fi delivering many simultaneous channels of transmit and receive on a single radio in 2.4GHz & 5GHz – called Wi-Fi Spectrum Slicing. MCSR powers its products. Edgewater Wireless WiFi3™ powered access point products enable unique service providers to plan, build, and deploy reliable, high-capacity services (such as VoWiFI) for high-density & data demand in any environment.

Edgewater delivers the highest channel density available on the contemporary market. It uses Edgewater Wireless patented technology, which enables numerous channels on a single chip. Accordingly, aggregate output on a single WiFi3™ powered AP will outperform traditional, single channel APs.

Edgewater Wireless Systems has released a powerful new Wi-Fi Spectrum Slicing Development Kit powered by Edgewater’s MCSR™ chipsets. The Company’s pioneering Dev Kit 2.0 delivers a complete hardware and software package for open source developers to create an ecosystem of apps unlocking the power of Spectrum Slicing to the residential and enterprise Wi-Fi markets.

Mr. Andrew Skafel, Chief Executive Officer of Edgewater Wireless Systems, said, “The latest release of our Dev Kit builds on the success of our earlier release, which was instrumental in securing our first enterprise design-win. We’re excited and proud to offer our latest Dev Kit and expect there is a myriad of applications to be developed.”

Edgewater Wireless Systems, Inc. (KPIFF), closed Saturday's trading session at $0.0329, up 88.00%, on 111,050 volume with 9 trades. The average volume for the last 3 months is 47,887 and the stock's 52-week low/high is $0.009999999/$0.07.

Serica Energy plc (SQZZF)

Wallet Investor, Invest Tribune, Dividend Investor, Market Screener, Seeking Alpha, Stockhouse, MarketWatch, Trading View, Wallmine, Investors Hangout, Pink Investing, The Street, 4-Traders, Guru focus, and Barchart reported earlier on Serica Energy plc (SQZZF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Serica Energy plc is an independent upstream oil and gas company headquartered in London, United Kingdom (UK). The Company has operations focused on the UK North Sea where it has the full range of exploration, development, as well as production assets. Serica’s primary emphasis is on building a portfolio of properties where it can use its technical, commercial and operating capabilities to add value to existing producing assets and to explore and develop new reserves. Established in 2004, Serica Energy lists on the OTC Markets.

Serica has proved the success of the above-mentioned model via its producing asset, Erskine, in which it is a partner with Chevron and Chrysaor. On November 30, 2018, the Company completed the acquisition of interests in the Bruce, Keith and Rhum fields where it also took over as field operator. These fields are a combination of late-life and mid-life, mainly gas producing assets where further investment can enhance recovery and extend field life.

The Bruce, Rhum and Keith fields in the UK Northern North Sea produce through the Serica operated Bruce facilities, consisting of three platforms with accommodation for up to 160 people. Serica Energy has drilled 23 wells since its inception in 2004, 17 as operator.

Serica has drilled wells across a broad spectrum of offshore geographies. This includes the UK, Ireland, Indonesia and Vietnam. As an operator, 14 of the 17 wells drilled by the Company encountered oil or gas, six of which were of commercial significance, leading to the discovery of Columbus in the UK North Sea and Kambuna in Indonesia.

Since its direct involvement in the Erskine operations, Serica Energy has contributed to a major improvement in the asset’s production levels. Serica is the development operator for Columbus. It also developed the Kambuna field before selling its operated interest on favorable terms to the Company in 2008.

Serica Energy plc (SQZZF), closed Saturday's trading session at $1.65, up 73.6842%, on 3,100 volume with 4 trades. The average volume for the last 3 months is 1,207 and the stock's 52-week low/high is $0.25/$1.606058.

Abattis Bioceuticals Corp. (ATTBF)

Greenbackers, Promotion Stock Secrets, InvestorIntel, Stockgoodies, Cannabis Financial Network News, PennyStocks24, CFN Media Group, Goldman Small Cap Research, and Information Solutions Group reported previously on Abattis Bioceuticals Corp. (ATTBF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abattis Bioceuticals Corp. is a life sciences and biotechnology company based in Vancouver, British Columbia (BC). The Company aggregates, integrates and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. It has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. Abattis Bioceuticals also has an operations office in Langley, BC.

The Company’s brands include Vergence Naturals™. Additionally, Abattis is working to acquire exclusive intellectual property (IP) rights to agricultural technologies to be utilized in the extraction and processing of botanical ingredients and compounds.

The Company has, through its operations and wholly-owned subsidiaries, a broad array of capabilities. These include cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

Abattis Bioceuticals has a 90 percent ownership interest in Gabriola Green Farms, Inc. Gabriola is a BC company. Gabriola has applied for a license to produce (LP) under the Access to Cannabis for Medical Purposes Regulations (ACMPR) on Gabriola Island, one of the gulf islands in the Strait of Georgia off the coast of BC. Currently, Gabriola has plans for an approximately 26,000 square-foot production facility to produce medical-grade marijuana located on 18 acres in the agricultural land reserve on Gabriola Island, BC.

Abattis is continuing its development work on a hemp-infused cannabinoid-rich, THC-free craft beer with Faculty Brewing Co. It is also continuing its development work on nanoemulsified and liposomal platforms for transmucosal delivery of cannabinoid-rich hemp oil with the University of British Columbia.

Abattis Bioceuticals has an investment in XLABS Therapeutics (ONT), Inc. Abattis and XLABS will be launching a new cannabis laboratory in Belleville, Ontario, to serve Ontario’s increasing cannabis sector.

This past November, Abattis Bioceuticals announced that it acquired Select Strains. Select Strains has a portfolio of greater than 140 laboratory-tested craft cannabis strains. Abattis hopes to leverage these via licensing arrangements, clone fulfillment, tissue culture and strain patenting services and ultimately through its late-stage ACMPR licensed producer applicant, Gabriola.

Recently, Abattis Bioceuticals announced that, further to its new release dated December 7, 2018, it entered into a definitive share exchange agreement with 1157016 B.C. Ltd., d/b/a NutriVida, a private arm’s length company, whereby Abattis will acquire 100 percent of the issued and outstanding common shares of NutriVida. NutriVida has been well-known in the fertilizer and cultivation industry for the past 25 years. It has extensive knowledge and experience in researching, innovating, manufacturing, and selling all-natural, bio-safe, fertilizers and plant nutrients.

Abattis Bioceuticals Corp. (ATTBF), closed Saturday's trading session at $0.01325, up 89.2857%, on 8,326,503 volume with 246 trades. The average volume for the last 3 months is 315,596 and the stock's 52-week low/high is $0.003/$0.076999999.

Metrospaces, Inc. (MSPC)

Stockwolf, Investors Hangout, Street Insider, Penny Stock Tweets, Stockhouse, Stock of the Week, InvestorsHub, OTC Markets, ClayTrader, Small Cap Network, Insider Financial, Barchart, WalletInvestor, MarketWatch, Emerging Growth, and Street Register reported earlier on Metrospaces, Inc. (MSPC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Metrospaces, Inc. is a real estate investment and development Company. It acquires land, designs builds, and develops, then resells condominiums and Luxury High-End Hotels, chiefly in urban areas of Latin America. The Company is operated by a premier group of real estate and investment professionals and entrepreneurs located in New York, New York; Miami, Florida; and Buenos Aires, Argentina. Metrospaces’ current projects are in Buenos Aires, Argentina, and Caracas, Venezuela.

A start-up real estate private equity firm, Metrospaces is based in New York City. The Company’s refocusing of its business plan to U.S.-based projects is now complete. Metrospaces has strong relationships with Investment Bankers, Real Estate Entrepreneurs, Political Leaders and High Net-Worth Individuals around the world. The Company’s focus is on mid-sized deals.

Metrospaces looks to use its international relationships in financing and real estate developers to find co-investment and development opportunities in home building, residential and hotel. Furthermore, it will invest in operating companies that are real estate based. This includes hotel operators and senior facilities operators. Metrospaces will also invest in corporate reorganization.

The Company focuses on joint ventures (JV’s) with established players. Metrospaces’ majority shareholders have partnered with Investors on elite properties including The London BLVGARI 5 Star Hotel and are presently involved in negotiations for the development of a number of elite luxury properties in South America.

Metrospaces has executed a JV Agreement with Prohotels of Argentina. The agreement calls for the development of four new hotels in the coming three years.

Recently, Metrospaces announced a management decision to focus capital resources to its Cannabis-related real estate Company, CannPartners. At present, Metrospaces is looking at two properties, one in Connecticut and one in California. The Company is also keeping a strong focus on the New York market. It is in advanced talks for acquisition of those properties.

Mr. Oscar Brito, Metrospaces Executive President, said, “The continuing legalization of medical and recreational cannabis growing and distribution will continue in the US for the foreseeable future. Many investors are focusing on the grow, distribution and ancillary industries such as paraphernalia etc. However, even with the billions of dollars currently being invested in the cannabis industry, there are very few institutional investors solely focusing on the cannabis-related real estate side of the business. In our opinion, this represents a once-in-a-generation opportunity to buy distressed and real estate located in out-of-favor locations across the U.S.”

Metrospaces, Inc. (MSPC), closed Saturday's trading session at $0.0001, up 9900.00%, on 105,077,999 volume with 61 trades. The average volume for the last 3 months is 1,281,548 and the stock's 52-week low/high is $0.000000999/$0.000099999.

Towerstream Corp. (TWER)

MadPennyStocks, MarketClub Analysis, Money Morning, PennyOmega, OTCBB Journal, OTCMagic, Penny Picks, KingPennyStocks, BUYINS.NET, Damn Good Penny Picks, Penny Stock Prodigy, CoolPennyStocks, Epic Stock Picks, Hit and Run Candle Sticks, HotOTC, Investing Futures, MicroCapDaily, Investment Contrarians, Jason Bond, Broad Street, BullRally, PennyInvest, and ChartPoppers reported on Towerstream Corp. (TWER), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Towerstream Corp. is a leading Fixed-Wireless Fiber Alternative business.  The Company delivers high-speed Internet access to businesses. Together with its subsidiaries, it provides fixed wireless broadband services and delivers access over a wireless network transmitting over regulated and unregulated radio spectrum to commercial customers in the United States. Towerstream has its corporate office in Middletown, Rhode Island.

Towerstream announced earlier in 2018 that its Board of Directors started evaluation of strategic repositioning of the Company as it moves to take advantage of its existing important assets in major American markets. In association with the announcement, Towerstream launched a determined focus on indirect and wholesale channels and the retention of Bank Street Group LLC as its independent financial advisor to explore strategic alternatives with such broadband carriers.

Towerstream provides broadband services in twelve urban markets. These include New York City, Boston, Los Angeles, Chicago, Philadelphia, the San Francisco Bay area, Miami, Seattle, Dallas-Fort Worth, Houston, Las Vegas-Reno, and the greater Providence area.  Towerstream has constructed 175 Major Points of Presence (POPs). The Company positions its POPs on the tops of buildings.

Towerstream is a last-mile facilities-based provider. It owns its entire network. The Company totally bypasses the local exchange carrier and cable providers. Its solution to businesses either complements or replaces existing Internet connections. Towerstream provides property managers, building owners, and their commercial tenants a redundant and reliable dense urban network. This network directly connects to the Company’s fiber backbone. 

Towerstream has its Single Tenant Internet Solution. This solution is for customers not in On-Net buildings. The Single Tenant Internet Solution provides primary and back-up dedicated internet access as a faster and less expensive alternative to fiber. On-Net refers to the extensive number of buildings in Towerstream’s 12 coverage markets now lit for On-Net Business Internet Service. The Company’s On-Net Service provides businesses within its continually growing portfolio of On-Net buildings with dedicated and symmetrical Internet connectivity.

Towerstream Fixed Wireless features fast installation, guaranteed 99.99 percent uptime backed by the Company’s industry leading SLA, and scalability. It also features faster than fiber, true redundancy, and symmetrical speeds.

Towerstream Corp. (TWER), closed Saturday's trading session at $0.75, up 102.7027%, on 4,975 volume with 8 trades. The average volume for the last 3 months is 397 and the stock's 52-week low/high is $0.150000005/$2.00.

The QualityStocks Company Corner

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs Inc. (NASDAQ: SGLB) was featured today in a publication from PennyStocks.com, examining several penny stocks, which they currently note as attractive plays.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Saturday's trading session at $3.07, up 6.9686%, on 2,700,618 volume with 10,650 trades. The average volume for the last 3 months is 433,142 and the stock's 52-week low/high is $1.95000004/$11.1999998.

Recent News

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of pressure-based instruments, consumables and platform solutions to the worldwide biotechnology and other industries, today announced that its proposed acquisition partner Cannaworx Inc. has set December 2020 as the commercial launch date for its patented immune booster supplement: ImmunaZin(TM). To view the full press release, visit https://ibn.fm/YSeDU

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions — all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Saturday's trading session at $2.50, up 14.6789%, on 81,152 volume with 198 trades. The average volume for the last 3 months is 20,582 and the stock's 52-week low/high is $0.600600004/$4.48999977.

Recent News

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings (NASDAQ: FRSX) (TASE: FRSX), an innovator in automotive vision systems, today announced that the European Commission, through the Horizon 2020 framework program, has awarded a funding grant of nearly 20 million Euro for the All Weather Autonomous Real logistics operations and Demonstrations (“AWARD”) consortium to develop and operate safe autonomous heavy-duty vehicles in harsh weather conditions in a variety of different scenarios. As part of the project, Foresight will provide its QuadSight(R) multispectral vision solution, and is expected to receive approximately one million USD. According to the update, the AWARD project will be rolled out in 2021 for a period of three years. To view the full press release, visit https://ibn.fm/9phIp

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed Saturday's trading session at $1.58, up 16.1765%, on 19,354,320 volume with 50,140 trades. The average volume for the last 3 months is 1,657,006 and the stock's 52-week low/high is $0.460999995/$1.95000004.

Recent News

The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER)

The QualityStocks Daily Newsletter would like to spotlight The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER).

The Alkaline Water Company Inc. (NASDAQ: WTER) (CSE: WTER) was featured today in the 420 with CNW by CannabisNewsWire. Recent data on cannabis sales in the state of California shows that sales have been doing well despite the pandemic situation. The California Legislative Analyst’s Office (LAO) released a report this week noting that sales figures recorded during summer and revised numbers from 2019 show that the market has grown. This trend has also been observed in various states that have legalized marijuana such as Oregon and Illinois.

Founded in 2012, The Alkaline Water Company Inc. (CSE: WTER) (NASDAQ: WTER) is headquartered in Scottsdale, Arizona. Its flagship product, Alkaline88®, is a leading premier alkaline water brand available in bulk and single-serve sizes, along with eco-friendly aluminum packaging options. With its innovative, state-of-the-art proprietary electrolysis process, Alkaline88® delivers perfect 8.8 pH balanced alkaline drinking water with trace minerals and electrolytes and boasts the company’s trademarked label ‘Clean Beverage’. Quickly being recognized as a growing lifestyle brand, Alkaline88® launched A88 Infused™ in 2019 to meet consumer demand for flavor-infused products. A88 Infused™ flavored water is available in six unique all-natural flavors, with new flavors coming soon. Additionally, in 2020, the company launched the A88CBD™ brand, featuring a broad line of topical and ingestible products. These products are made with lab-tested full and broad-spectrum hemp and include salves, balms, lotions, essential oils, bath-salts, CBD infused drinks, tinctures, capsules, gummies and powder packs.

Innovation and Expansion

Founded in 2012, The Alkaline Water Company began with a mission to create the best-tasting water in the world. At the time, there were two emerging trends in health-conscious consumers: a growing interest in the alkaline diet and perceived health benefits of pink Himalayan rock salt. By combining these two concepts in an alkaline water and trademarking the name Alkaline88, The Alkaline Water Company began offering what it calls the smoothest tasting Clean Beverage™ in the U.S. enhanced-water category.

Now a top bulk alkaline-water brand (the company reported record sales in March and April 2020, surpassing March and April 2019 numbers by 114% and 171%, respectively), The Alkaline Water Company is committed to growing its national footprint through innovation and expansion. That mindset was evident as the company introduced eco-friendly aluminum bottles and branched out into flavor-infused waters; the company currently offers six different flavors: peach/mango, lemon/lime, raspberry, watermelon, blood orange and lemon.

The company’s commitment to innovation may be most evident in its newest product line: A88CBD. This line of CBD-infused products includes tinctures, capsules, gummies, salves, balms, hand and foot lotions, essential oils, bath bombs and bath salts, as well as CBD-infused drinks, water and beverage shots. These quality, CBD-infused offerings are all made with lab-tested, full-spectrum hemp and are conveniently packaged and perfect for on-the-go or at home use.

In addition, The Alkaline Water Company has implemented an aggressive growth strategy, with numerous organic initiatives focused on national multichannel, mass-market expansion through a direct-to-warehouse model and co-packing facilities that are strategically located within 600 miles of 95% of the U.S. population. In addition to this strong brick-and-mortar approach, the company recently launched a B2C e-commerce platform (www.A88CBD.com) and aggressive digital-marketing campaigns.

Clear Advantages in a Growing Market

With consistent growth year over year, the company reported $32.2 million in revenue in fiscal 2019 and has emerged as a growth leader in the functional (value-added) waters space, which is the fastest-growing segment of the bottled water industry.

The Alkaline Water Company’s efforts are focused on its clear competitive advantages, including its strong marketing (the inclusion of alkaline in product names); existing grocery channels, which feature excellent relationships and a nationwide broker network; distinctive branding; proprietary technology, which produces great-tasting, high-quality water, infused drinks and other products; and price, with a broad range of products in all formats, from bulk bottles to single serve.

As the company focuses on strategic growth, it is eyeing the impressive potential of a market that is on a strong upswing. Annual bottled water sales have now surpassed soda consumption, with soda sales in the United States having declined by $1.2 billion over the past five years. Some research indicates that the global bottled water market will reach an estimated $280 billion this year, while the CBD market is forecast to top $20 billion by 2024.

With its products available in all major trade channels, including grocery stores, drug stores, c-stores and big-box retailers, The Alkaline Water Company is also looking to expand into new spaces, such as health and beauty, hospitality and specialty retailer locations.

Seasoned Management Team

The Alkaline Water Company is led by an experienced team focused on the company’s core strategy of building a national retail footprint and extending its lifestyle brands into other consumer packaged goods categories.

Richard A. Wright, President, CEO and Co-Founder of The Alkaline Water Company Inc., oversees all aspects of the business, successfully guiding the company through strategic opportunities and delivering greater than 50% growth since the company’s inception. A passionate and versatile leader with a strong track record of innovation, collaboration and achieving goal-driven results, Wright is a serial entrepreneur with more than 41 years of experience. Early in his career, he spent years at one of the ‘Big Four’ accounting firms, working his way up to Regional Director of Tax and Financial Planning. As a CPA, entrepreneur and former CFO, Wright brings extensive knowledge of finance, operations, sales and marketing to the team, and he has participated in hundreds of M&A transactions throughout his career.

David Guarino, CFO, Secretary, Treasurer and Director, earned a Bachelor of Science in accounting and a Master of Accountancy from the University of Denver. From 2008 to 2013, Guarino was President and a Director of Kahala Corp., a worldwide franchisor of multiple quick-service restaurant brands with locations in 49 states and more than 25 countries. From 2014 to 2015, Guarino was President of HTI International Holdings Inc., a technology company focused on forward osmosis water filtration technology.

Frank Chessman, National Sales Manager, is a graduate of the University of Southern California’s Marshall School of Business. He spent 25 years with Ralph’s Grocery, Kroger’s largest division, working at many levels before ultimately becoming Vice President of Advertising & Marketing. He then served 14 years as Executive Vice President at Simon Marketing. Chessman has more than a decade of experience in the beverage manufacturing industry.

Brian Sudano, Director, is managing partner of Beverage Marketing Corporation and BMC Strategic Associates. Sudano’s experience covers nearly the entire beverage industry, from energy drinks to wine, with special expertise in beverage alcohol by virtue of varied industry experience across a broad range of projects. Sudano manages several major clients, providing ongoing strategic and market advice and leading projects in strategic planning, market entry analysis and planning, sales/distribution, business modeling, brand repositioning and international opportunity assessment. He has spoken at many beverage industry events and is a contributing editor at Beverage World magazine.

Aaron Keay, Chairman, has been a successful investor, entrepreneur and financier to multiple small cap and startup companies over the last decade. During his time with these companies, he served in advisor, board-member and senior-management roles. His experience ranges across multiple sectors in mining, biotech, health and wellness, tech and cannabis, where he has invested and raised more than $500 million.

The Alkaline Water Company Inc. (NASDAQ: WTER), closed Saturday's trading session at $1.09, up 0.925926%, on 3,145,328 volume with 5,197 trades. The average volume for the last 3 months is 1,554,963 and the stock's 52-week low/high is $0.400000005/$2.5999999.

Recent News

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0)

The QualityStocks Daily Newsletter would like to spotlight MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0).

MustGrow Biologics (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) has been granted an exclusive patent licensing from the University of Idaho in Moscow, Idaho (https://ibn.fm/vW2Ag). The patent is in connection with a natural biopesticide mustard-based treatment of stored produce and other foods. The ability the treatment may have for sprout suppression of potatoes is gaining particular interest in Idaho, which is the largest producer of potatoes in the country.

MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FRA: 0C0) is an agricultural biotech company focused on developing and commercializing natural biological solutions for high-value crops, including fruits and vegetables. The company uses novel compounds from the mustard plant to provide superior and safer alternatives to current synthetic chemicals used as pesticides, fungicides and nematicides. Management & advisors own 22% of the company’s 37 million shares outstanding.

Leveraging its innovative platform, MustGrow effectively extracts the natural defense mechanisms of the mustard seed for broad use in crop production and protection. The company uses components of mustard seed to provide high quality, organic pest control to growers facing challenges associated with soil-borne diseases and pests like nematodes. This company’s all-natural, effective, safe and easy-to-use solution is ideal for farmers looking to raise healthy crops without chemical pesticides amid growing concerns worldwide over the negative effects of chemical pesticide solutions.

MustGrow, which went public in 2019, was founded in Saskatoon, Canada, and is currently focused on disrupting the $65 billion global pesticide market with its 100% owned and patented mustard-derived technology. Canada produces 28% of the global mustard crop and is the world’s largest exporter, with a 57% market share.

TerraMG and Pipeline

The company’s technology extracts the mustard plant’s natural organic compounds, which, when combined with water, form Allyl isothiocyanate (AITC) and serve as a natural defense mechanism for the plant against pests and diseases. MustGrow’s mustard-derived technology acts as both a natural bio-pesticide and as a non-selective bio-herbicide.

There are currently more than 110 independent third-party trials that confirm the safety and efficacy of MustGrow’s solutions, potentially positioning the company as a leading provider of safe plant protection solutions in a market that is gradually eliminating the use of chemical compounds.

MustGrow’s primary product at the moment is the new liquid formulation TerraMG, which has the potential to compete against existing chemistries on both efficacy and price. Its initial target market is as a pre-plant soil bio-pesticide for use with higher-value crops such as fruits and vegetables. This liquid formulation is safe and easy to transport and has already demonstrated its efficacy against several pests and diseases.

In addition to its use as a pre-plant soil treatment, TerraMG has significant potential for multiple applications in several other markets, which is expected to aggressively expand the company’s IP portfolio. MustGrow has already confirmed or is in the process of testing multiple applications of TerraMG, including fruit and vegetable soil fumigation ($1.2 billion estimated global market), container fumigation ($2 billion estimated global market), tobacco nematode and disease fumigation ($4 billion estimated global loss), non-selective herbicide ($13 billion estimated global market), food-borne pathogens ($15 billion estimated global market) and more.

The company anticipates registration approval for the liquid formulation (TerraMG) as a pre-plant bio-pesticide for soil-borne diseases and pests from the EPA (United States) and PMRA (Canada) in 2021. The company already has EPA and PMRA approval for the product’s granular form.

Currently, MustGrow’s pipeline also includes:

  • TerraMG, a pre-plant soil bio-pesticide, for:
    • Fruit & Vegetable – currently in Phase 4
    • Turf & Ornamental – currently in Phase 4
    • Tobacco – currently in Phase 4
    • Potatoes – currently in Phase 4
    • Canola – targeting Clubroot Disease – currently in Phase 3: Advanced Development/Field Trials
    • Bananas – targeting Fusarium wilt TR4 – currently in Phase 1: Proof of Concept/Laboratory
    • Pulse Crops – targeting Aphanomyces – currently in Phase 1: Proof of Concept/Laboratory
  • Non-Selective Bio-Herbicide – targeting noxious or resistant weeds – currently in Phase 2: Early Development/Greenhouse
  • Storage Bio-Pesticide for Bulk Grain, Fresh Produce – targeting toxins, diseases and insects – currently in Phase 1: Proof of Concept/Laboratory
  • Storage Bio-Pesticide for Shipping Containers – targeting fungus, invasive pests and diseases – currently in Phase 1: Proof of Concept/Laboratory
  • Bio-Pesticide for Foodborne Pathogens – targeting E. coli, salmonella, Listeria, human pathogens, etc. – currently in Phase 1: Proof of Concept/Laboratory

Market Opportunity

The protection of crops with synthetic chemical pesticides represents a $65 billion-dollar global market that is expected to grow in the coming years as the global population grows and needs more food. This number doesn’t include bio-pesticide sales, which are projected to increase to $8.5 billion by 2025, with a CAGR of 14.7%. MustGrow, with its natural bio-pesticide, is targeting not only the bio-pesticide market, but also the global synthetic chemical market so as to help replace harmful synthetic pesticides and provide a natural biologic that has the efficacy of controlling pests and disease compared to synthetic chemicals in some instances.

Management Team

Corey Giasson is the President, CEO and Director of MustGrow. He is an entrepreneur focused on the agriculture, mining, real estate and oil/gas industries, primarily in the Canadian province of Saskatchewan. Giasson is co-founder and director of Legacy Capital Corp. This private equity company focuses on participating in management buyouts of strong, sustainable cash flowing businesses. He has an MBA and B.Sc. in Agriculture Economics from the University of Saskatchewan.

Colin Bletsky is COO and Director of MustGrow. He grew up in Eastern Saskatchewan on his family’s third-generation farm, growing canola, wheat and oats. The majority of his time is spent helping other organizations and farmers grow their businesses – locally and globally. Bletsky has a Bachelor of Science in Agriculture from the University of Saskatchewan and executive education from the London School of Business and INSEAD.

Todd Lahti is the company’s CFO. He has extensive experience evaluating and managing biotech, agricultural and oil/gas start-up companies by working directly on financing transactions, mergers and acquisitions, business development, corporate strategy, technology transfer and operations setup. Lahti is a Chartered Financial Analyst and a Chartered Professional Accountant.

Brad Munro is Chairman of MustGrow. He is the President and CEO of Bittercreek Capital Corp., a private investment and advisory firm. He has extensive corporate finance and investment experience in the natural gas and oil industries, among others. Munro has a Bachelor of Commerce from the University of Saskatchewan.

MustGrow Biologics Corp. (OTCQB: MGROF), closed Saturday's trading session at $0.641, up 3.2206%, on 117,994 volume with 26 trades. The average volume for the last 3 months is 9,412 and the stock's 52-week low/high is $0.009999999/$0.944999992.

Recent News

Gage Cannabis Co.

The QualityStocks Daily Newsletter would like to spotlight Gage Cannabis Co..

Gage Cannabis is strengthening its position as Michigan’s leading high-quality craft cannabis brand and operator. With a commitment to build the fastest-growing cannabis brand in the state, Gage recently began offering recreational marijuana at its Lansing, Michigan location (https://ibn.fm/nqJ5R). To view the full article, visit https://ibn.fm/5YSCk

Gage Cannabis Co. is a leading vertically integrated operator in the cannabis industry led by the former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC), Bruce Linton. The company is currently focused exclusively on the Michigan market, working with the declared goal of building the fastest growing cannabis brand in the state.

One of the reasons Gage targeted Michigan as its location of choice is due to the state’s fast-growing legal cannabis market and consumption habits amongst consumers. In 2018, Michigan became the 10th state to legalize the recreational use of cannabis. In light of such favorable market dynamics, Gage opened its first medical provisioning center (dispensary) shortly after, in 2019. The company now has 13 medical or adult-use locations open or in the works, with an additional 10+ planned to open during 2021. Gage’s current portfolio features 19 Class C cultivation licenses across four cultivation assets and three processing licenses.

Current Asset and Brand Portfolio

Gage’s current brand portfolio consists of five unique product classes: flower products, edibles, hardware, concentrates and vape pens/disposables.

The company has already created relationships with a wealth of exclusive brand partners, including some of the most illustrious brands in the country. Notably, Gage’s exclusive partnership with Cookies, one of the most well-respected cannabis lifestyle brands in the United States, illustrates Gage’s operational prowess in cultivating quality flower and operating its branded retail stores. Today, Gage operates the 8 Mile Cookies location in Detroit, Michigan, which is one of the top performing dispensaries in the state despite being a medical-only dispensary.

Committed to providing only products of the highest quality, Gage uses small-batch, indoor-grown, high-quality cannabis that is hand-trimmed and hung to dry. Gage ensures that every gram of cannabis sold is consistently of the highest quality and offers a superb customer experience.

The company currently has four cultivation assets, located at Monitor Township (expansion planned), Harrison Township, Warren and Lenox Township, and it operates one processing facility located in Harrison Township, with plans to operate another two processing facilities in Monitor Township and Lenox.

Its operating dispensaries include Ferndale (adult-use), Adrian (adult-use), Lansing (adult-use), Traverse City (medical) and Detroit (Cookies establishment – medical). Additional dispensaries coming soon include Battle Creek (adult-use), Kalamazoo #1 (adult-use), Bay City (adult-use), Grand Rapids (medical), Buena Vista (medical), Center Line (medical), Kalamazoo #2 (Cookies establishment – adult-use) and Lenox Township.

The company offers delivery within a one-hour radius of its dispensaries – a footprint that encompasses an estimated 90% of Michigan’s population.

Financial Highlights

In Q1 2020, the company recorded sales of $5.8 million. This number grew substantially in Q2, reaching $11.9 million. Management estimates Q3 sales at roughly $13.1 million, marking a 157% growth in sales from January to September 2020, within a year of operations.

This increase reflects the company’s significant expansion efforts since the beginning of 2020. Starting with only 200 pounds per month, Gage now estimates its monthly cultivation capacity at more than 1,000 pounds of product.

This increase in cultivation capacity has helped Gage promote rapid growth through its retail locations. Average basket size, which refers to the retail value of each consumer transaction, is estimated at $85 for the Michigan cannabis industry. As of August 2020, Gage has an average basket size of $180 at its locations, more than double the state average.

Michigan Medical and Adult-Use Marijuana Market Size

The recreational marijuana market in Michigan is expected to rival the numbers currently seen in Nevada and Colorado by 2023. Approximately 3% of Michigan’s residents are medical marijuana cardholders – a much higher rate than many other medical markets – leading Brightfield to predict that the state’s recreational market could triple in size between 2020 and 2023 (https://ibn.fm/9cO0h).

Michigan saw a steady increase in sales for the first three quarters of 2020, with a recorded growth rate of 502% from January to August. In August alone, $109 million in cannabis sales occurred within the state. The Marijuana Regulatory Agency estimates that the potential market size for cannabis within the state is around $3 billion.

Neither Gage nor the state has seen any significant drop in sales in the wake of the COVID-19 pandemic. On the contrary, demand has continued to grow steadily, as dispensaries were among the few businesses deemed essential and permitted to operate throughout the shutdown. All Gage and Cookies locations have remained operational, offering curbside pickup.

Plans to Go Public in Q1 2021

Gage Cannabis is currently planning a Canadian listing for the first quarter of 2021 (https://ibn.fm/V73dL). Additionally, Gage intends to launch a Regulation A+ offering of up to 28,571,400 subordinate voting shares priced at $1.75 per share, for gross proceeds of up to $50 million before offering expenses, assuming all shares are sold (https://ibn.fm/FteTi), but it has not yet made an announcement regarding the launch of that financing.

A Regulation A+ offering, also called a mini-IPO, allows companies to raise capital without actually listing shares on a stock exchange.

Management Team

Bruce Linton is the Executive Chairman of Gage Cannabis. He joined the company in 2019 and is the founder and former CEO and Chairman of Canopy Growth Corp. (TSX: WEED) (NYSE: CGC). Mr. Linton has extensive executive and board experience in a variety of industries and is considered to be a pioneer in the global cannabis industry. He provides incomparable support to the company’s strategic and capital markets efforts.

Michael Hermiz is the Co-Founder and Director of Gage Cannabis, and he is also the founder of a federally licensed producer in Canada. Mr. Hermiz has had great success in various industries, including real estate, mortgage, telecommunications, import, export and many others.

Fabian Monaco is Gage’s President and Director. He previously worked at XIB Financial Inc., GMP Securities L.P. and Scotiabank. In addition to his vast investment banking and legal background, Mr. Monaco has 10+ years of capital markets experience. His advisory experience in the cannabis industry is also extensive.

Dr. Rana Harb is a Director of Gage Cannabis. She has 25+ years of experience handling research, compliance, quality assurance and regulatory affairs. A significant portion of her regulatory and compliance history is in the cannabis industry. Dr. Harb has worked for many pharmaceutical companies worldwide, dealing with regulatory agencies such as the FDA, the EMA and Health Canada.

Mike Finos is the President (USA) and a Director of Gage Cannabis. He is the former COO of Horizon Global, the world’s number one towing accessories company. He has experience with start-ups, M&A and business integration with both private and publicly traded companies. With 20+ years of operational leadership expertise, Mr. Finos has extensive knowledge relating to supply chain logistics, manufacturing and information technology.

David Watza is the Chief Financial Officer of Gage Cannabis. He is an experienced C-Suite executive and former CFO and board member of Perceptron Inc. (NASDAQ: PRCP). Mr. Watza has 30+ years of experience in finance, accounting, and operations, including time as a public company CFO.


Recent News

chart

Rritual Superfoods Inc.

The QualityStocks Daily Newsletter would like to spotlight Rritual Superfoods Inc..

Rritual, a plant-based consumer brand, is a private company that manufactures premium products including small-batch elixir powders and premium shots made from medicinal mushrooms and adaptogenic herbs. With a mission to help people meet the demands of modern life with style and ease through mushroom adaptogen products, Rritual stands distinct among other brands. To view the full article, visit https://ibn.fm/hGgn4

Rritual Superfoods Inc. is a private company founded in 2019, whose declared purpose is to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets.

The company manufactures premium plant-based products such as small-batch elixir powders, and each product features mindfully selected medicinal mushrooms and adaptogenic herbs. Pursuing customers with various need-states, Rritual offers products that fit every lifestyle.

Suite of Premium Rritual(TM) Products

Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.

The initial product line includes:

  • Chaga (immune booster) – Full of bioactive polysaccharides, Rritual’s Chaga blend combines the Chaga mushroom with Eleuthero root for optimal immune system benefits.
  • Lion’s Mane (brain booster) – Designed to support cognitive function and brain health, Lion’s Mane is paired with Rhodiola root. The elixir can also help the body manage stress.
  • Reishi (stress support) – Rich in polysaccharides, triterpenes, amino acids and fatty acids, the Reishi blend is infused with Ashwagandha root. This combination aims to help the body and mind fight anxiety, with long term effects that may improve quality of sleep for those with restless minds.

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Hart said in a news release.

Rritual CEO David Kerbel noted that the company is proud to bring together age-old mushroom consumption practices and data-backed research to create new formulas that meet the needs of modern consumers. “Whether to relieve stress, increase mental output or boost immunity, we want to be a trusted and effective component of a consumer’s daily health and wellness routine,” he added.

Rritual Timeline

According to its investor presentation, Rritual has already fulfilled most of the milestones it set for Q1 and Q2 2020 as part of its growth and development timeline. So far, the company has completed formulation R&D, product line development, test marketing, brand development, logistics partnerships and agreements, initial distributor partnerships, seed financing and the phase one launch of its product suite.

Rritual E-Commerce Rollout Strategy

The company’s strategy for e-commerce rollout success consists of direct-to-consumer (D2C) sales through the use of multiple online platforms and through team connections to facilitate rapid expansion within the market.

In the first stage, Rritual will use its own website and Amazon to facilitate its D2C initiative, followed by leveraging its team connections to sell products through planned specialty e-commerce channels such as Costco, CVS, Walmart, and Vitacost using preexisting relationships.

Brick-and-Mortar Rollout Strategy

Using partnerships already in place with The Jet Collective and leveraging the preexisting connections of its team for direct discussions with global retail brands, Rritual’s brick-and-mortar strategy features a two-stage rollout that targets 15 leading retailers.

In the first stage, Rritual aims to launch with four non-competing chains, while utilizing best practice agreements (320 Sprouts stores, 330 H-E-B stores, 240 Meijer stores and 1,600 Publix stores). In stage 2, distribution is expected to advance to additional retail establishments (100 Wegmans stores, 77 Fresh Thyme stores, 440 Whole Foods stores, 120 Shaw’s stores, 400 Stop & Shop stores, 300 Wakefern/Shoprite stores, 610 Vitamin Shoppe stores, 90 Bartell Drug stores, 40 Giant Eagle market district stores and 1,800 Target stores), while collaboration with Kroger will take place within two sub-markets (300 Ralphs stores and 120 Harris Teeter stores).

Market Growth Outlook

As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth. At this time, no dominant brand is in place, and there remains an absence of a premium brand to lead the category.

The entire functional food market is currently valued at more than $275 billion, with global shifts supporting wellness and a 7.9% CAGR forecast through 2025. Demand for functional mushrooms is also growing, with a forecast rise from $23 billion to $34 billion by 2024 as a result of growing popularity due to the superfood’s unique properties that have been shown to boost immunity, cognitive function and more. The worldwide functional mushroom market is projected to exceed $50 billion by 2025, with recent data indicating an increase in demand for key mushroom varieties of up to 800%.

Management Team

David Kerbel, CPC, is CEO of Rritual and has over 30 years of senior experience in retail, brokerage and CPG industries. From 2008 to 2011, Kerbel served as Senior Vice President of Sales for Celsius Holdings Inc., helping that company achieve a number of important milestones. During his tenure, Celsius grew its retail sales from $400,000 to a multimillion-dollar figure, developed nationwide representation with CROSSMARK Inc. and established distribution with industry giants such as 7-Eleven, Ralph’s, C&S, Costco, BJ’s Wholesale, CVS, Walgreens, Walmart, Rite Aid, Target, Duane Reade and Stop & Shop. In total, Celsius’ new distribution stemming from Kerbel’s direct efforts led to $36 million in incremental sales in 2010 alone. He also implemented new procedures that led to a 10 percent reduction in operating expenses. Kerbel brings tremendous experience to the Rritual team, as well as vital relationships with industry leaders such as Walmart, Costco, Kroger, Walgreens, CVS, 7-Eleven, Safeway, Publix, Sprouts and more.

Warren Spence is the COO and a Director of Rritual. He has over 25 years in the food and beverage industry. His roles within the industry have included senior positions with brands like Red Bull and Olivieri. His specialization is in supply chain and operations systems. He was appointed Head of Supply Chain for Nude Beverages in 2019.

Dr. Mike Hart, MD, is the President of Rritual. His work has been published in peer-review journals about therapies involving cannabis and ketamine. His outspoken stance on these subjects landed him an appearance on the Joe Rogan Experience Podcast in 2019. On-air, he discussed the use of psychedelic medicines as a treatment for mental health conditions, including PTSD.

Stacie Gillespie is CCO and Director of Formulations for Rritual. She has over 25 years of leadership in the branding and product strategies used by wellness companies. She has leveraged this expertise for companies such as Aura Cacia, MegaFood and Gaia Herbs. She is the creator of multiple award-winning consumer health products.

Sarton Molnar-Fenton is Vice President of Sales-USA for Rritual. She started her career with Vitamin Water, with other large companies under her belt, including Danone, as a District Manager. She worked with Nestle on its Tribe Hummus brand and played an integral part in relaunching the brand, gaining category share and establishing product development partnerships with companies like Trader Joe’s. She also played a key role in launching the Hydralyte brand in the United States.

Scott Naccarrato is the company’s Vice President of Sales-Canada. He is experienced in sales with a deep connection in retail. Recently, he worked with Nutiva, assisting in the pioneering of Organic MCT oil, healthy fats and the plant-based protein categories. He is data-oriented in his approach, which has resulted in over $100 million in sales and double-digit year-over-year growth for the brands of which he has been a part.

Investment Considerations

  • Rritual’s suite of premium functional mushroom and adaptogenic elixirs is designed to offer various health benefits, such as increased immunity, cognitive function, stress management and more.
  • The company’s products are expected to be available online through Rritual’s site and Amazon by fall 2020.
  • The Rritual team has extensive ties and influential relationships with leading retail businesses, providing a wide market for growth.
  • The functional mushroom industry has no clear and dominant leader, allowing Rritual to target this role with its premium products. Rritual is currently the only premium brand on the market.
  • The global functional mushroom market is expected to exceed $50 billion by 2025, putting Rritual in the position for success.
  • Functional mushroom demand is expected to rise from $23 billion to $34 billion by 2024.

Recent News

chart

CannAssist International Corp. (OTCQB: CNSC)

The QualityStocks Daily Newsletter would like to spotlight CannAssist International Corp. (OTCQB: CNSC).

CannAssist (OTCQB: CNSC), a unique, enhanced cannabidiol (“CBD”) company, recently announced SEC approval of its Reg. A+ Tier 2 Filing as of Oct. 13, 2020, and an opportunity for investors to purchase shares at a set price stated in filing. To view the full press release, visit: https://cnw.fm/g8BIt. Also today, CannabisNewsWire released a report featuring the company which details various investment considerations and how the company is “One to Watch.”

CannAssist International Corp. (OTCQB: CNSC), owner of Xceptor Labs, is a biotechnological pharmaceutical and wellness company marketing the Xceptol consumer brand.

CannAssist, a Delaware corporation, was established in May 2017 and is headquartered in San Diego County, California.

2018 Farm Bill and CBD Market Size

Signed into law in December 2018, the Agriculture Improvement Act of 2018 (2018 Farm Bill) removed hemp from its classification as a Schedule I drug under the Controlled Substances Act of 1970.

There are over 100 known cannabinoids within the hemp plant. The two most commonly utilized cannabinoids are THC (tetrahydrocannabinol) and CBD (cannabidiol). Cannabinoids have been shown to affect the endocannabinoid system within the human body, which is why CBD has demonstrated effectiveness as a therapeutic option when delivered through the right absorption avenues.

The 2018 Farm Bill is expected to have a sustained impact on the growth of the cannabidiol market and related sectors. In 2018, the global cannabidiol market was valued at $4.6 billion, and it’s expected to increase almost sixfold by 2025, reaching $23.6 billion (https://ibn.fm/PL6PO).

This growth is expected to provide multiple opportunities to CannAssist and its high-quality, high-performance brands, including products currently under development. Based on current revenue from licensing agreements, retail sales and the Xceptol brand’s international distribution, the company expects to reach first-year sales of $5 million. With additional products in the pipeline and an unwavering commitment to quality and effectiveness, the company expects to see steady sales growth in the years ahead.

Xceptor Labs

Xceptor Labs is an R&D and raw material manufacturing company that partners with TakaUSA, in Coppell, Texas, for contract manufacturing and production services.

CiBiDinol Technology

Xceptor Labs’ technology, CiBiDinol, is formulated using a proprietary process developed by CannAssist Founder Mark Palumbo. It is specifically designed to address many critical issues with oil-soluble CBD molecules, including delivery, bioavailability and short shelf-life. This technology provides the basis for Xceptor Labs and Xceptol consumer products.

CiBiDinol is believed to provide CBD in a format that is more in line with the body’s natural bioactivity. The company’s proprietary processes are used to combine CBD molecules with penetration enhancing cyclodextrin, effectively modifying the CBD molecule’s surface and rendering it water dispersible. This technology enhances absorption through the skin and gut.

The company believes that CBD products created using its CiBiDinol technology offer more predictable potency and enable reduced dosage requirements. This technology clears the way for a wide variety of products, including many oil-soluble active ingredients and highly effective consumer product applications.

Independent Testing

Third-party testing has confirmed that products made with CiBiDinol demonstrate a 400 percent increase in skin penetration as compared to regular CBD in oil carriers alone, as well as a 300 percent higher absorption rate in the gut. The company believes that the results indicate that the amount of CBD needed to achieve targeted endpoints can be significantly lower, resulting in lower costs for manufacturers and consumers with little to no side effects.

“Oversight of manufacturing and third-party testing of this ingredient produced consumer products designed to provide clinicians and consumers safe, effective, and affordable treatment options to address their health and wellness concerns,” Palumbo said in a news release.

CiBiDinol is currently being evaluated for safety by the National Science Foundation for Global Recognition and has been submitted to the FDA’s bulk drug substance program. The company is developing a commerce pathway in each state’s pharmaceutical distribution network through the National Board of Pharmacies. The company aims to capture increasing market share through product extensions and advancements by seeking critical third-party analysis and physician feedback regarding its proprietary technology’s attributes. Xceptor Labs intends to offer licensing arrangements for brand-consumer companies.

Xceptol Products

CiBiDinol technology is the foundation for Xceptor Labs and the Xceptol line of products, including topical creams, capsules, tinctures and pet drops. The Xceptol line began launching its products in September 2020, and it currently has five National Drug Code topical pain creams utilizing ingredients registered with the FDA.

Xceptol products will be sold online, through Range Me, as well as through national and international retail and pharmaceutical distributors. Marketing for Xceptol products is planned through multiple social media campaigns including using celebrities and former athletes associated with Freedman Sports Promotional Relations.

Xceptol is establishing sales channels in North America, Central America, South America, South Africa, the EU, the UK and the Philippines.

Management Team

Mark Palumbo, CEO and Founder, is an entrepreneur, scientist and executive with over 30 years in the health care, laboratory and manufacturing industries. His entrepreneurial endeavors include a successful personal care industry distribution company, a currently owned and operated tissue culture laboratory and Xceptor Labs, now part of CannAssist International.

Marla Palumbo, President, is a health care professional and registered nurse with over 30 years of experience in the industry. She handles sales, patient advocacy, patient care and general management. Marla Palumbo has effectively developed and grown a personal care distribution company with significant year over year increases in sales. Her management and organization skills were instrumental in the early development of Xceptor Labs, leading to its CannAssist International public company status.

Dr. Rahul Dixit, MD, Medical Director, is a doctor of gastroenterology at Providence St. John’s Medical Center in Santa Monica, California. He was part of a double fellowship with the University of Miami in Gastroenterology and Hepatology/Liver Transplant at Johns Hopkins Hospital. He has over 20 years of experience with cannabis and hemp-related products.

Takako McGowan, Managing Director, Founding Member and Owner of TakaUSA, brings 40 years of experience in manufacturing and consumer product research & development to the CannAssist team.

Camron Elizabeth, Managing Director-Sales and Marketing, is an entrepreneur and leader who has brought immense success to the companies with whom she has worked. As Founder and CEO of Platinum Pack, Elizabeth was responsible for all aspects of its success in bringing products from concept to completion and successful sell-through on the retailer’s shelf. She has been in the beauty industry for over 40 years.

Benjamin Perlstein, VP of Operations, has been a part of the health care and business development field for over 25 years. As a surgical technologist, he has experience as a clinical application specialist and materials manager.

Braden Traub, Director of Marketing and Customer Development, is an entrepreneur and business owner with 10 years of experience in the health and fitness industries. Traub also has skills and experience as a tax resolutionist and legal document preparer.

Safe Harbor for Forward-Looking Statements

Forward-looking statements are inherently subject to risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, including, without limitation, the following: the timing and nature of any capital raising transactions; the Company’s ability to offer products and services for use by customers in existing and new markets; the Company’s ability to deliver in a timely fashion and to its customers’ satisfaction the products purchased; the risk of competition; its ability to find, recruit and retain personnel with knowledge and experience in selling products and services in existing and new markets; its ability to manage growth; and general market, economic and business conditions. Additional factors that could cause actual results to differ materially from those anticipated by the Company’s forward-looking statements are under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in its Annual Report on Form 10-K for the fiscal year 2019 and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, all filed with the Securities and Exchange Commission. Forward-looking statements are made as of the date hereof, and the Company expressly disclaim any obligation or undertaking to update forward-looking statements.

CannAssist International Corp. (OTCQB: CNSC), closed Saturday's trading session at $0.30, even for the day, on 2,600 volume with 2 trades. The average volume for the last 3 months is 386 and the stock's 52-week low/high is $0.200000002/$0.50.

Recent News

Brain Scientific Inc. (OTCQB: BRSF)

The QualityStocks Daily Newsletter would like to spotlight Brain Scientific Inc. (OTCQB: BRSF).

A recent report published by Allied Market Research estimates that the global electroencephalography (“EEG”) equipment market was $1.4 billion in 2018 and is expected to reach $1.99 billion by 2026, growing at a CAGR of 4.5% from 2019 to 2026 (https://ibn.fm/Jmxjq). As a commercial-stage, healthcare company dedicated to developing innovative medical devices in the neurological diagnostics space, Brain Scientific (OTCQB: BRSF) seems well placed to capitalize on the growing EEG equipment market. Also today, the company was featured in a publication from BioMedWire, examining how t it will participate in AES2020 – the all-new virtual event for epilepsy professionals in academia, clinical practice, industry and advocacy. Slated to take place on Dec. 4–8, 2020, the American Epilepsy Society's Annual Meeting is the largest meeting and exhibition in the world to share common scientific and clinical interests in epilepsy and clinical neurophysiology. To view the full press release, visit: https://ibn.fm/SfmN0

Brain Scientific Inc. (OTCQB: BRSF) is a commercial-stage health care company focused on developing innovative and proprietary medical devices and software. With a mission of modernizing brain diagnostics by employing cutting edge technologies to bridge the widening gap in access to quality care, the company offers two FDA-cleared products that provide next-generation solutions to the neurology market.

The company’s proprietary, clinical-grade neurological devices are supported by its intellectual property portfolio featuring patents in the United States, China and Europe.

Brain Scientific’s first commercialized devices, NeuroCap(TM) and NeuroEEG(TM), are designed to disrupt the current electroencephalogram (EEG) market by offering cost-effective and disposable substitutes to existing solutions, allowing medical professionals to collect diagnostic information quickly.

The company’s goal is to improve diagnostics by leveraging artificial intelligence and machine learning processes to analyze a database of brain readings as a method of detecting seizures and dementia. The company is also working to improve patients’ access to neurological care.

Headquartered in New York, Brain Scientific and its predecessor (and now wholly owned subsidiary, MemoryMD Inc.) was founded in 2015 and went public in 2018.

Brain Scientific’s first phase of development, from 2018 to 2019, saw the inception of portable, clinical-grade, easy-to-use neurological devices. The second phase, currently ongoing, aims to create cloud-based, secure infrastructure to transmit patient data between patients and their neurologists. The company’s third phase of development is scheduled for 2021-2022 and is expected to focus on the use of AI-assisted diagnostic analysis to increase the efficiency, consistency and accuracy of neurology specialists.

NeuroCap(TM) – Disposable EEG Headset

The NeuroCap is a disposable pre-gelled EEG headset featuring 22 electrodes and 19 active EEG channels, all adhering to the international 10-20 system. The NeuroCap was FDA-cleared in 2018. The headset can be used for recording EEGs in virtually any setting, including urban and rural emergency departments, neurology clinics, urgent care clinics, ICUs, nursing homes, assisted living facilities and remote clinical research labs.

Through a universal cable adapter, the NeuroCap is compatible with other EEG amplifiers. The cap also works in parallel with Brain Scientific’s NeuroEEG amplifier, initiating EEG studies in less than five minutes.

The company is currently seeking FDA approval for additional features for the NeuroCap, as the device has the potential to fill a gap in EEG testing availabilities during the current coronavirus pandemic: in October 2020, Brain Scientific filed an Emergency Use Authorization (EUA) application. The EUA is required for the rapid distribution of the NeuroCap device to emergency departments, intensive care units and other treatment centers to administer prescriptive EEGs safely on critically ill patients or those suspected of being diagnosed with COVID-19.

With more than 80 percent of hospitalized patients infected with COVID-19 displaying neurological symptoms, the NeuroCap could prove to be a valuable device by offering fast testing with limited contact between technicians and patients.

NeuroEEG(TM) – Miniature and Portable Wireless EEG Amplifier

The NeuroEEG is a compact, portable and affordable wireless EEG amplifier intended for prescription use. The 16-channel, FDA-cleared, clinical-grade device acquires, records, transmits and displays electrical brain activity for patients of all ages.

Both the NeuroCap and NeuroEEG are delivered by MemoryMD Inc., a wholly owned subsidiary of Brain Scientific.

Products in Active Development

Currently, Brain Scientific and MemoryMD are working on leveraging their existing products and drawing from ongoing research to develop and commercialize the next generation of solutions for the brain diagnostics market. The devices under development are being designed to address the following issues:

Routine EEG

  • NeuroCap-8 is an 8-channel EEG cap. The reduced number of electrodes is vital in emergency room situations, where the time it takes to set up the EEG is critical.

Pediatric EEG

  • NeuroCap Pediatric is positioned to become the first disposable and pre-gelled headset available for the pediatric market.

Long-Term Monitoring

  • NeuroCap LTM for adult and pediatric patients is a disposable cap designed to monitor rhythmic and periodic patterns for up to 72 hours, providing essential diagnostic capabilities.
  • NeuroEEG 24 Channel Amplifier is a portable and wireless amplifier with over 24 hours of battery life.

Artificial Intelligence

  • Brain E-Tattoo is a minimally invasive four-channel EEG electrode designed for long-term monitoring.
  • An AI database of brain biomarkers collects data on both normal and abnormal brain data to detect neurological diseases. The goal is for machine learning algorithms to enhance understanding of brain-behavior related to epilepsy, memory dementia and pre-Alzheimer’s diagnostics.

Telemedicine

Brain Scientific is expanding the vision for telemedicine in neurology. The company aims to address the current acute neurologist shortfall (20 states have less than 10 neurologists per 10,000 patients) through the use of teleneurology.

 

Partnership with Marketing Brainology

Brain Scientific has a longstanding partnership with Marketing Brainology, a neuromarketing firm using neuroscience approaches to understand consumer behavior. In 2019, Marketing Brainology conducted a study using NeuroCap and NeuroEEG to determine the most effective Super Bowl commercials.

“Thanks to Brain Scientific’s NeuroCap and NeuroEEG, we are able to better understand the art and science of the human decision-making process,” Michelle Adams, Ph.D, Founder of Marketing Brainology, stated in a news release.

In April 2020, Marketing Brainology again conducted a study leveraging Brain Scientific’s disposable EEG cap to determine how brains were reacting to COVID-19 messaging. Subjects were presented with multiple media impressions, and Marketing Brainology analyzed their responsive biomarkers. The results identified the most effective messaging for engaging with an audience during a crisis.

Market Outlook

The current global market for EEG devices is estimated at $956.1 million. It is expected to rise with a CAGR of 8.7% from 2019 to 2026, reaching $1.6 billion in value by 2026, according to Grandview Research.

In total, there are approximately 6,150 hospitals in the U.S., according to the American Hospital Association. Critically, though, just 254 of those hospitals are certified Level 4 Epilepsy centers with 24/7 EEG coverage. Since very few non-Level 4 centers have extensive EEG tech coverage, this creates a significant opportunity for Brain Scientific to bridge the gap by providing over 5,900 hospitals with lower cost amplifiers and disposable EEG caps.

The company also see opportunities to work with other businesses, such as EEG manufacturers hoping to package Brain Scientific’s solutions with their products, which could greatly expand Brain Scientific’s addressable target market.

Management Team

Dr. Baruch “Boris” Goldstein, Ph.D., is co-founder and Chairman of Brain Scientific. He is a seasoned executive with a proven talent for aligning global business strategies with established and emerging management teams. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital for the development of innovative companies and startups in diverse industries, including financial services, biomedicine, alternate energy and new materials, as well as groundbreaking work in artificial intelligence. His recent achievements include important advancements in neurology and unlocking the potential of AI correlations and machine learning applied to life sciences and medical research. He built a suite of first-to-market companies as a technology-oriented leader, including Ryah Medtech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems. He also co-founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics.

Dr. Nikolay Kukekov, Ph.D., is a Director of Brain Scientific and a partner at HRA Capital. Before joining HRA Capital, Kukekov was Managing Director of Healthcare Investment Banking at Summer Street Research. His scientific background includes a bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder. He earned his Ph.D. in neuroscience from Columbia University – College of Physicians and Surgeons in New York.

Stuart Bernstein is the company’s Vice President of Marketing. He was recently named to the role after spending the first part of his professional career in senior technical management roles with Fortune 500 companies such as NCR (NYSE: NCR), IBM (NYSE: IBM) and Control Data Corp. He was the CEO of BioSignal, an EEG medical device company. He is also a co-founder of several software engineering and telemedicine firms. One of them, Brain Saving Technology, is now Specialist on Call (SOC Telemed) – a leading telemedicine company that powers over 850 facilities for teleneurology, telepsychiatry and critical care telemedicine with over 200 physicians.

Brain Scientific Inc. (OTCQB: BRSF), closed Saturday's trading session at $1.50, off by 11.7647%, on 1,200 volume with 5 trades. The average volume for the last 3 months is 3,823 and the stock's 52-week low/high is $0.100000001/$3.00999999.

Recent News

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF)

The QualityStocks Daily Newsletter would like to spotlight Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF).

The announcement by Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) that its investee company, PowerTap, has engaged NASA-based hydrogen engineering firm, Cryotek, as an engineering design partner will give an added fillip to the value of Clean Power’S investment in the fast-growing hydrogen fuel-cell vehicle market. Clean Power Capital is an investment holding company with investments in the health industry and renewable energy industry, has recently increased its focus on opportunities in the renewable energy industry, including fuel-cell technologies. The collaboration between PowerTap and Cryotek will advance PowerTap’s efforts to commercialize its patented hydrogen filling technology, and therefore increase the value of Clean Power’s investment in fuel-cell technologies and PowerTap.

Clean Power Capital Corp. (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) is an investment holding company that focuses on investing in and providing early-stage financing to both public and private businesses. Since its original listing with the Canadian Stock Exchange (“CSE”) on January 23, 2019, the company has made investments in a number of different businesses in a variety of industries, including the energy and cannabis sectors. As per the company’s investment policy, its primary goal is to identify and capitalize on high-return investment opportunities presenting the ability to achieve capital appreciation and liquidity.

Clean Power Capital continues to be opportunistic in evaluating prospects across the renewable energy, bio-medical, pharmaceutical and naturopathic sectors, both as an investor and as an operator. The company’s main focus at the moment is to identify such opportunities in the renewable energy industry, including wind, solar and geothermal power and hydrogen and fuel cell technologies, as well as in the biomedical, pharmaceutical and naturopathic sectors, which may include medical or recreational cannabis.

Clean Power Capital currently has 10 investments in a variety of sectors and successfully held nearly C$120 million in investments during the past fiscal year (https://ibn.fm/8oktZ). It returned capital to its shareholders through the distribution of its interest in AgraFlora Organics International Inc. in May 2020 (https://ibn.fm/FRAvq).

Headquartered in Vancouver, British Columbia, Clean Power Capital was formerly named Organic Flower Investments Group Inc. As of November 10, 2020, the company officially changed its name to Clean Power Capital and started trading on the CSE under new ticker symbol ‘MOVE’.

PowerTap Acquisition, Hydrogen Fueling Infrastructure Collaboration

In alignment with its updated investment policy, a reconstituted investment committee and a revised strategy to reflect its focus on the renewable energy market, Clean Power Capital recently completed the acquisition of a 90 percent equity interest in California-based PowerTap Hydrogen Fueling Corp.

Leveraging an impressive portfolio of IP and advanced deployed technologies developed over two decades via substantial investments and partnerships, PowerTap is working on building and expanding a hydrogen filling station network, initially across North America. The company believes that its platform has a significant advantage over other hydrogen fueling stations, because it has a smaller physical footprint and further has the capacity to produce hydrogen fuel on site. As most other hydrogen fueling stations buy hydrogen for storage at higher costs, PowerTap’s model is believed to be exponentially more cost-effective and expandable.

Clean Power Capital’s investment and acquisition will allow PowerTap to step up its efforts and begin work on the hydrogen fueling station network in stages, starting with engineering and design, ongoing development of PowerTap’s third generation product and, finally, licensing & permitting and site preparation. Development is expected to begin in Q4 2021 with engineering and design. Overall, the initial portion of the project is expected to cost $17 million, with Clean Power Capital and PowerTap planning to secure government financing and credit, as well as equity, debt and convertible debt offerings, to fund the infrastructure’s development.

PowerTap technology is already deployed across multiple hydrogen fueling stations in public and private enterprises spanning California, Maryland, Massachusetts and Texas. The company plans to deploy its hydrogen fueling infrastructure at existing truck stops and gas stations across the country, beginning with up to 1,000 stations within the next three to five years. At the moment, there are roughly 70 active hydrogen fueling stations operational and available to consumers in the United States.

Hydrogen Industry Outlook

The project is expected to bring significant opportunities for PowerTap and Clean Power Capital on the fast-growing hydrogen market, driven by a worldwide focus on clean energies and environmentally friendly fueling solutions for the transportation industry.

Hydrogen-powered vehicles come with tremendous advantages over gas, diesel and even electric vehicles in terms of cost per mile, fueling time and driving range, as well as boasting significantly lower emissions. Well-established vehicle manufacturers such as Hyundai, Toyota, Daimler and Volvo are already including hydrogen-powered cars in their product lineups, and Nikola Motors has announced plans to manufacture hydrogen electric long-haul vehicles.

“As an experienced developer of technology in an important area that is finally having its time as a green but also economically compelling energy option, PowerTap is intent on becoming a leading part of the multi-billion dollar hydrogen fueling space,” PowerTap CEO Raghu Kilambi explained in a news release on October 28, 2020 (https://ibn.fm/oaXem).

A recent industry report developed by a coalition of major oil and gas, power, automotive, fuel cell and hydrogen companies indicates that the sector is expected to grow to $140 billion a year in revenue by 2030, creating 700,000 jobs in the U.S. alone (https://ibn.fm/UMI5q). According to Fuel Cell and Hydrogen Energy Association President Morry Markowitz, the sector could expand to $750 billion a year in revenue and 3.4 million jobs by 2050.

The U.S. is already engaged in the hydrogen economy, having more than half of the global number of fuel cell vehicles and investing hundreds of millions of dollars a year, but the country can greatly expand its global energy leadership by scaling up operations in the hydrogen economy, per the industry report.

With the upcoming change in administration in January 2021, the U.S. is expected to renew its commitment to clean energy. Moreover, the U.S. federal government is expected to invest significantly in clean energy and related infrastructure, including hydrogen, according to PowerTap.

“As the U.S. federal government has previously invested in the PowerTap technology, we are optimistic that we will have a seat at the table when USA clean energy/hydrogen infrastructure spending initiatives are designed,” Kilambi added.

Management Team

Joel Dumaresq is the CEO and interim CFO of Clean Power Capital. He is a proven executive with extensive operational and senior management experience in mining, energy and alternative energy, as well as the cannabis and hemp space. Dumaresq began his career in the corporate finance space, having spent 12 years with RBC Dominion Securities. He brings 30 years of experience in the financial sector to the company, has been instrumental in raising over $250 million in venture capital finance, and he has personally managed a number of successful public listings.

Brendan Purdy serves as a director of Clean Power Capital. An experienced businessperson who has led five different companies, Purdy brings years of experience in different industries, including cannabis, blockchain and data security, gaming, mining and energy, and finance and law. He received a graduate degree from the University of Ottawa and an undergraduate degree from the University of Western Ontario.

Theo van der Linde serves as a director of Clean Power Capital. He is a Chartered Accountant with over 20 years extensive experience in finance, reporting, regulatory requirements, public company administration, equity markets and financing of publicly traded companies. He has served as a CFO & Director for a number of TSX Venture Exchange- and Canadian Securities Exchange-listed companies over the past several years. His industry experience spans the financial services, manufacturing, oil & gas, mining and retail industries. More recently, van der Linde has been involved with future use trends of natural resources, as well as other disruptive technologies.

Raghu Kilambi is the CEO and CFO of PowerTap Hydrogen. He is a seasoned investor and entrepreneur with over 25 years of global business experience in public and private investments, building businesses and creating shareholder value. He has raised over $1 billion of equity and debt capital for private and public companies and been involved in many M&A acquisitions and exits.

Clean Power Capital Corp. (OTC: MOTNF), closed Saturday's trading session at $1.10, off by 8.3333%, on 95,546 volume with 79 trades. The stock's 52-week low/high is $0.0315/$1.75.

Recent News

AzurRx BioPharma Inc. (NASDAQ: AZRX)

The QualityStocks Daily Newsletter would like to spotlight AzurRx BioPharma Inc. (NASDAQ: AZRX).

AzurRx BioPharma Inc. (NASDAQ: AZRX) was featured today in a publication from BioMedWire, examining how The National Institutes of Health extended the COBRE grant valued at over $11 million for the University of Delaware biomedical research team. This will allow the team to proceed to phase 2 of their research.

AzurRx BioPharma Inc. (AZRX) is a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins.

The company’s lead drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients suffering from cystic fibrosis and chronic pancreatitis.

AzurRx has already completed two Phase 2 clinical trials for MS1819 and is currently pursuing approval through parallel monotherapy and combination therapy pathways.

The company was founded in 2014 and is headquartered in New York City, with scientific operations in Langlade, France, and clinical operations in Hayward, California.

MS1819 Clinical Trials

The two current ongoing clinical trials for MS1819 in cystic fibrosis (CF) are the Phase 2b Option 2 monotherapy trial and the Phase 2 combination therapy trial, using MS1819 together with porcine pancreatic enzyme replacement therapy (PERT), the current standard of care. Pending the Phase 2b trial outcome, the company intends to initiate a Phase 3 trial in cystic fibrosis.

  • Phase 2b CF Option 2 Trial – The study was initiated in Q3 2020, using MS1819 doses in enteric capsule form (2240mg and 4480mg). Topline data for the trial is anticipated in Q1 2021.
  • Phase 2 CF Combination Trial – The study was initiated in Q4 2019, using daily dose levels of PERT in combination with MS1819 dosages (700mg, 1120mg and 2240mg). Topline data is anticipated in Q2 2021.

These trials are currently addressing the treatment of EPI in patients with cystic fibrosis and chronic pancreatitis – an established global market with an estimated value in excess of $2 billion that has been growing at a CAGR greater than 20% over the past five years.

Results from AzurRx’s Phase 2b Option 2 trial of MS1819 in cystic fibrosis patients demonstrate that the non-porcine MS1819 lipase is well-tolerated by patients, with no significant safety signals observed at the 2240mg daily dose level.

“[W]e have evaluated four different enteric capsules and identified the best suitable formulation for MS1819 that provides gastroprotection of enzyme content and delayed release into the duodenum,” James Sapirstein, President & CEO of AzurRx, stated in a September 2020 news release (https://ibn.fm/27t4W). “Our clinical program continues to advance, and we are determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients.”

Financial Highlights

As of July 2020, AzurRx had raised gross cash capital of $22.1 million, including $15.2 million from Series B convertible preferred stock and warrants in July 2020 and $6.9 million from convertible promissory notes and warrants in December 2019 and January 2020. Notably, AzurRx solidified its financial position and created an effectively debt-free balance sheet by exchanging substantially all of its outstanding convertible notes into the Series B convertible preferred stock financing.

The company secured an additional $2.5 million in French Research Tax Credits, received in 2020, for the years 2017-2019 (https://ibn.fm/Qxk7O).

In a letter to shareholder, Sapirstein noted that ensuring the company maintains sufficient capital to support its business operations has been a key focus. He further stated that the company is in “a financially secure position” to complete its two Phase 2 MS1819 clinical trial programs and to begin preparations in 2021 for a pivotal Phase 3 study.

The company has no current plans to access additional financing, as it believes it has enough cash to fund existing operational and clinical objectives through Q3 2021.

Management Team

James Sapirstein is the President and CEO of AzurRx BioPharma. He was previously the CEO and a board member for ContraVir Pharmaceuticals Inc., which is now known as Hepion Pharmaceuticals Inc. (NASDAQ: HEPA). Mr. Sapirstein has almost 36 years of experience in the pharmaceutical industry, with expertise in drug development and commercialization. He currently serves on the Emerging Companies and Health Section boards of the BIO (Biotechnology Innovation Organization) and is Chairman Emeritus of BioNJ. He earned his Bachelor’s degree in Pharmacy from Rutgers University and has an MBA in management from Fairleigh Dickinson University.

Daniel Schneiderman is the Chief Financial Officer of AzurRx. He previously served as the CFO of Biophytis SA and its U.S. subsidiary, Biophytis, Inc., clinical-stage biotechnology companies focused on the development of pharmaceutical candidates for age-related diseases. He was appointed to the AzurRx position in January 2020, bringing to the team over 18 years of experience in capital markets and finance operations. Mr. Schneiderman holds a degree in economics from Tulane University.

James Pennington, M.D., is the Chief Medical Officer of AzurRx. Before joining the team, he was the Chief Medical Officer and Senior Clinical Fellow for 11 years at Anthera Pharmaceuticals. Before becoming a part of the biotech industry, Dr. Pennington was on the Medical Faculty of Harvard Medical School for 10 years. He received his medical degree from Oregon Health & Science University.

Martin Krusin is the Senior Vice President for Corporate Development at AzurRx. He has 20 years of experience in business development, strategic marketing, financing and operations in the health care, financial services and consulting sectors. Before joining AzurRx, he was the VP for Business Development at FluoroPharma Medical Inc. Mr. Krusin received his MBA from Columbia Business School in finance and marketing, an MPhil. in political economy from Oxford University and a BA in international relations from Swarthmore College.

Dinesh Srinivasan, Ph.D., is the Vice President for Translational Research at AzurRx. He has over 15 years of experience leading drug discovery and development in the pharmaceutical industry. He began his career as a post-doctorate fellow at Roche Palo Alto. Dr. Srinivasan received his MSc in Biotechnology from the University of Mumbai, India, and a Ph.D. in Pharmacology and Toxicology from the University of Arizona – Tucson.

Ted Stover is the Product Development Director at AzurRx. He joined the company in 2020 to oversee CMC and Project Management. Before joining AzurRx, he spent 20 years focused on manufacturing operations and analytical method development for all stages of pharmaceutical drug development. Mr. Stover earned his MBA from the University of Florida.

AzurRx BioPharma Inc. (AZRX), closed Saturday's trading session at $0.775, off by 1.9608%, on 1,025,101 volume with 854 trades. The average volume for the last 3 months is 147,342 and the stock's 52-week low/high is $0.370867997/$1.93830001.

Recent News

Pure Extracts Technologies Corp. (CSE: PULL)

The QualityStocks Daily Newsletter would like to spotlight Pure Extracts Technologies Corp. (CSE: PULL).

Pure Extracts Technologies Corp. (CSE: PULL), headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms. The firm is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

The Company’s business model consists of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to sell under their own brands; and white labelling, supplying products, including edibles and custom formulated oils, in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Market Position

The psychedelic and functional mushroom industries are among the fastest growing in North America. As the industry transitions from dry biomass to extracts, many companies are unprepared for this new opportunity. The global medicinal mushroom market is expected to grow by $13.88 billion annually by 2024.

When assessing investment strategy, market analysts suggest that psychedelics are more comparable to biotech than to cannabis. Unlike traditional biotech, however, psychedelics can claim years of human consumption. Because their efficacy and safety are already well understood, the hurdles for development are likely to be lower. As known molecules, psychedelics won’t spend as much time in discovery and pre-clinical development.

Current research is finding psychedelic benefits including anti-tumor, anti-viral, detoxification, immune function, and mental wellness. As such, psychedelic compounds are now being examined by leading medical research and academic institutions for treatment of depression, PTSD, anxiety, bi-polar disorder, obesity, narcolepsy, OCD, Alzheimer’s, ADHD and drug and alcohol dependence. In 2020, the FDA granted breakthrough therapy status to psychedelics for treatment-resistant depression, with approvals anticipated in 2021.

Pure Extracts is well positioned to partner with organizations planning to develop both functional and psychedelic products. A dealer’s license with Health Canada will enable buying, selling and producing of psychedelics in an EU-GMP-compliant environment. The Company’s 10,000 square foot facility is designed for EU-GMP certification, which allows for international sales. The Company has signed NDAs to explore joint development endeavors for Q4 2020 product launches, as well as an advisory agreement with Dr. Alexander MacGregor, founder of Transpharm Canada Inc. (“TCI”), the parent company of Toronto Institute of Pharmaceutical Technology, whose facility is a fully compliant Health Canada licensed Good Manufacturing Practice (“GMP”) manufacturing and testing facility and is a full-service clinical development business that provides clinical trial services to biotechnology companies.

Research on Psychedelics

Naturally occurring psychedelics, like psilocybin mushrooms, peyote and ayahuasca, have been used by humans for centuries. First seen as potentially medicinal in 1938 by a chemist at Sandoz Pharmaceuticals (now Novartis), the desired stimulant effect was unsuccessful and therefore the drug was shelved. Twenty years later, in 1958, Sandoz began selling lysergic acid diethylamide (LSD) to treat mental disorders. From 1950 to 1965, over a thousand scientific papers on these compounds were published. During the 1960s, however, psychedelics made their way out of the lab and onto the street. The war on drugs followed, and psychedelic research essentially ended.

Research continued slowly on the fringes. The Multidisciplinary Association for Psychedelic Studies was formed in 1986 with the goal of becoming a leading non-profit psychedelic pharmaceutical company. Still being researched, psychedelics’ primary and most common mechanism of action is agonism of serotonin receptors in the brain, which promotes serotonin production in order to regulate mood.

Growing societal awareness and acceptance of mental illness as a legitimate disease due, in part, to its increasingly prevalence have been a catalyst for a new search for innovative treatments. As such, interest in psychedelic medicines has been revived in recent years.

Extract Segment Leader with Cannabis

Canada’s cannabis industry is dominated by dried flower products. Extract products are estimated to represent only 13% of the market share. With no dominant brands in the cannabis sector, Pure Extracts is the development leader in this segment, which is estimated by Deloitte to be worth $2.7 billion annually. Pure Pulls, the company’s private label brand, is nationally recognized through compliant event sponsorship and ongoing product engagement.

Management Team

Pure Extracts is led by a team of dedicated professionals leveraging extensive industry knowledge.

Ben Nikolaevsky, the company’s CEO, has more than a decade of experience in corporate leadership roles across the natural products, agriculture and cannabis sectors. Nikolaevsky has served as CEO at Natura Naturals Inc. and Blue Goose Capital Corp., as well as market vice president at CIBC and chief credit officer & capital markets manager at IBM Global Financing Canada.

Doug Benville founded Pure Extracts and serves as the company’s COO. He is highly proficient in cannabis cultivation, system operations and oil extraction.

Alexander Logie, Pure Extracts’ vice president of business development, has over 30 years of experience in the financial services sector, having most recently served as interim CFO, COO and senior vice president of business development at Natura Naturals Inc., a licensed cannabis producer acquired at the start of 2019.

Andy Gauvin is vice president of sales for Pure Extracts. Gauvin is an accomplished senior sales leader with over 30 years of experience in the cannabis space. Gauvin also brings extensive knowledge of the complex federal and provincial regulatory environment to the Pure Extracts team.

Pure Extracts Technologies Corp. (CSE: PULL), closed Saturday's trading session at $0.60, off by 3.23%, on 228,728 volume with 56 trades. The average volume for the last 3 months is 295,647 and the stock's 52-week low/high is $0.52/$0.68.

Recent News

Sanwire Corp. (SNWR)

The QualityStocks Daily Newsletter would like to spotlight Sanwire Corp. (SNWR).

Sanwire (OTC: SNWR), focused on technologies for the entertainment industry, together with its wholly owned subsidiary Intercept Music Inc., today announced the completion of 25 online retail stores for its Intercept PLUS artists. Per the update, the online retail stores provide artists the ability to sell branded merchandise to their fans. Artists choose the products they wish to sell and promote, including logos, designs, prints, etc., and Intercept takes care of the rest for a share of the profits. To view the full press release, visit https://ibn.fm/i0n9y

Sanwire Corp. (SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

  • Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
  • Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
  • The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

  • Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
  • Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
  • Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (http://nnw.fm/NSrbE). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (http://nnw.fm/svrQt).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (http://nnw.fm/j0S0j). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

Sanwire Corp. (SNWR), closed Saturday's trading session at $0.0174, off by 8.4211%, on 1,239,669 volume with 56 trades. The average volume for the last 3 months is 547,561 and the stock's 52-week low/high is $0.0035/$0.100000001.

Recent News

Friendable Inc. (FDBL)

The QualityStocks Daily Newsletter would like to spotlight Friendable Inc. (FDBL).

Friendable (OTC: FDBL) has announced that its proprietary live-streaming platform, Fan Pass, has reached a significant milestone: 50 exclusive artist channels are now live across the different genres available, adding to the overall total of 70 live artist channels (https://ibn.fm/4actX). New November artist sign-ups bring almost 500,000 fans and followers with them.

Friendable Inc. (FDBL) is a mobile technology and marketing company focused on connecting and engaging users through its proprietary mobile and desktop applications. Launched July 24, 2020, the company’s flagship offering is designed to help artists engage with their fans around the world and earn revenue while doing so. The livestreaming platform supports artists at all levels, providing exclusive artist content ‘Channels’, LIVE event streaming, promotional support, fan subscriptions and custom merchandise designs, all of which serve as revenue streams for each artist.

With Fan Pass, artists can offer exclusive content channels to their fans, who can use their smartphones to gain access to their favorite artists, as well as an all-access pass to all artists on the platform. Additionally, the Fan Pass team will deploy social broadcasters to capture exclusive VIP experiences, interviews and behind-the-scenes content featuring their favorite artists – all available to fan subscribers on a free trial basis. Subscriptions are billed monthly at $3.99, or about the cost of downloading a couple of songs, and VIP experiences are available at a fraction of the cost of traditional face-to-face meetups.

Friendable Inc. was founded by Robert A. Rositano Jr. and Dean Rositano, two brothers with over 27 years of experience working together on technology-related ventures.

The Fan Pass Mobile & Desktop App

Friendable Inc. launched its Fan Pass platform as a solution for artists and their fans as the COVID-19 pandemic and the associated shutdown have continued to severely hamstring the entertainment industry as a whole. Through Fan Pass, the company aims to reach artists at all levels looking to alter their touring schedules to include ‘Virtual Touring’, new revenue sources and innovative fan engagement opportunities that are expected to become permanent fixtures of artists’ touring routines moving forward.

Fan Pass creates an ecosystem that embraces fans of all kinds, feeding diehard followers and developing lasting connections with more casual supporters. Through the app, qualified artists are provided with a custom designed, exclusive ’Fan Pass Channel’ where they can invite fans and social followers from anywhere around the world to join in chats and live events – allowing fans to experience all there is to see of an artist in one place. Artists earn revenue from monthly fan subscribers, merchandise sales, tickets sold for virtual streaming events and generally from all content views or impressions on their channels. All content views and sales of every kind are reported to each artist through their dashboards, including real-time payout and earnings information.

Fan Pass’ exclusive ‘All Access VIP’ option provides fans with access to content, such as:

  • Live performances or online concerts
  • Backstage meetups before, during or after events
  • Livestreams of studio sessions
  • Behind-the-scenes footage of music video and photo shoots
  • Special interviews and one-on-one videos
  • Streams highlighting the artists’ daily lives

The Fan Pass platform is extremely intuitive, bringing each artist through a streamlined onboarding process, including building out artist ‘Channels’, scheduling LIVE events and designing special edition merchandise to be offered solely through exclusive Fan Pass merchandise stores.

“With the global pandemic disrupting the entertainment industry in such a profound way, artists have had to look to digital distribution and live virtual performances in order to maintain any earning opportunities. Fan Pass and our team are determined to provide solutions and support to all artists, their fans and the industry in general. We are excited about the opportunity we have to shape the future of virtual entertainment, revenue generation and artist/fan engagement,” Robert A. Rositano Jr., CEO of Friendable Inc., stated in a news release.

Market Opportunity

Artists rely heavily on revenue streams that are not often seen by those without intimate industry knowledge. When it comes to traditional performances, the sale of VIP/backstage or meet & greet passes to boost revenue can often become the majority of the artist’s annual tour revenue. Data provided by one of the company’s original entertainment partners, The Kluger Agency (TKA), suggests that as much as 18-23% of artists’ annual tour revenue has historically been derived from these VIP experiences.

The World Economic Forum reports that, in 2020, the six-month-plus disappearance of live music concerts is estimated to have cost “the industry more than $10 billion in sponsorships,” and individual artists are feeling the loss the most. Fan Pass is helping to bridge this gap, providing more affordable virtual VIP experiences that can be offered simultaneously to fans around the world.

While it’s free for artists to join, Fan Pass leverages a monthly subscription model paid by fans to generate revenues. These revenues are shared with all channel artists. In exchange for its platform features, live streaming tools, bandwidth, processing and handling, Fan Pass earns platform fees on each separately ticketed event, as well as splits with each artist on subscriber fees and merchandise designed and sold on the platform.

The U.S. video streaming industry is expected to hit $7.08 billion in value in 2021, with an estimated 100 million internet users watching online video content every day, according to data from Livestream.com. The same report suggests that 45% of live video audiences would pay for exclusive, on-demand video from a favorite team, speaker or performer. Through Fan Pass, Friendable Inc. is uniquely positioned to capitalize on this opportunity.

Friendable App

The company’s second application, Friendable, is an all-inclusive platform where users can meet, chat and date. The app has exceeded 1.5 million total downloads, with over 900,000 historical registered users and more than 580,000 historical user profiles.

Friendable Inc.’s Next Phase of Growth

To facilitate its next phase of growth, Friendable Inc. is seeking an additional $1 million in equity investment, with a follow-on funding that meets or exceeds $5 million. The company intends to utilize its relationships to secure the lowest cost of capital available, as these funds will drive technology advancements, increase head count, fund marketing initiatives and secure additional celebrity talent aimed at bringing larger fan audiences to each released event. These initiatives will assist in building recurring monthly (fan) subscribers, effectively generating recurring monthly revenue for each artist, as well. The next phase of growth is expected to play a key role in accelerating the company’s download and conversion of data for subscription revenue and merchandise sales.

The company’s primary goal is to establish Fan Pass as a premier brand and mobile platform dedicated to connecting and engaging users around the world. In support of this goal, it has entered into a partnership with Brightcove targeting OTT platform expansion, including leaders such as iOS, Android, Apple TV, Android TV, Roku and WWW.

In the highly competitive video streaming market, Friendable Inc. has tapped into an unmet demand from today’s ever-present ‘omni-users’ for constant contact with celebrities and influencers. Via Fan Pass, the company offers investors an opportunity to gain a stake in an organization catering to this new breed of omni-users and their influencers.

The application’s potential is clearly illustrated by the interest it has generated in recent weeks. From September 4 to October 12, the Fan Pass platform added 246 new artists, accounting for a 410 percent increase in just six weeks.

“We are extremely encouraged by the ongoing swell of interest as the value of our Fan Pass platform continues to resonate in the artist community,” Friendable CEO Robert A. Rositano Jr. stated in a news release. “We believe the live streaming functionality, our full-circle offering and diverse revenue opportunities the platform offers will continue to drive exponential growth as management remains focused on building long-term shareholder value.”

Management Team

Robert A. Rositano Jr. is the co-founder and CEO of Friendable Inc. He oversees the daily management and operational duties of all areas of the business. He has over 20 years of experience as a serial entrepreneur, bringing in over $60 million in liquidity events for the companies he has created or managed. Before starting Friendable Inc. with his brother, Rositano was a founding member of the internet’s first IPO, Netcom Online Communications Inc. It was sold to ICG, then to EarthLink in 1995. He has been a co-founder of several successful ventures, including Simply Internet Inc., Nettaxi.com and America’s Biggest Inc., among others. He also authored one of the first web directories for MacMillan Publishers.

Dean Rositano is the co-founder and Chief Technology Officer of Friendable Inc. He handles the day-to-day operations and guides the technical direction of the company. He has over 15 years of executive management, financial management, high technology operations and internet architecture experience. Before co-founding Friendable Inc., Rositano co-founded several other companies, including Checkmate Mobile Inc. and Latitude Venture Partners LLC, among others.

Friendable Inc. (FDBL), closed Saturday's trading session at $0.015, off by 3.1633%, on 471,181 volume with 20 trades. The average volume for the last 3 months is 299,156 and the stock's 52-week low/high is $0.007799999/$0.509899973.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.